Review Article

Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis

Shashank Shrishrimal, Elizabeth A. Kosmacek, and Rebecca E. Oberley-Deegan

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA

Correspondence should be addressed to Shashank Shrishrimal; shashank.shrishrimal@unmc.edu and Rebecca E. Oberley-Deegan; becky.deegan@unmc.edu

Received 19 October 2018; Revised 6 December 2018; Accepted 12 December 2018; Published 6 February 2019

Guest Editor: Ayman M. Mahmoud

Copyright © 2019 Shashank Shrishrimal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Radiation-induced fibrosis (RIF) develops months to years after initial radiation exposure. RIF occurs when normal fibroblasts differentiate into myofibroblasts and lay down aberrant amounts of extracellular matrix proteins. One of the main drivers for developing RIF is reactive oxygen species (ROS) generated immediately after radiation exposure. Generation of ROS is known to induce epigenetic changes and cause differentiation of fibroblasts to myofibroblasts. Several antioxidant compounds have been shown to prevent radiation-induced epigenetic changes and the development of RIF. Therefore, reviewing the ROS-linked epigenetic changes in irradiated fibroblast cells is essential to understand the development and prevention of RIF.

1. Introduction

Fibrosis is characterized by an aberrant accumulation of extracellular matrix (ECM) proteins that result in the loss of normal tissue and organ function [1]. It is a significant cause of morbidity and mortality worldwide [2–9]. Exposure to radiation can trigger a condition known as radiation-induced fibrosis (RIF). The cell type involved in developing fibrosis is the myofibroblast, which primarily arises from fibroblasts upon radiation. Myofibroblasts can also arise from other cell types through the process of differentiation or by epithelial/endothelial-mesenchymal transitions [1]. Under normal conditions, myofibroblasts play a critical role in normal wound closure after injury [10]. After wound healing and restoration of ECM to homeostatic levels, the myofibroblasts undergo apoptosis [1]. However, wounds that fail to heal correctly contain persistent myofibroblasts that leave a keloidal or hypertrophic scar. These active myofibroblast cells do not undergo apoptosis after healing and continue to damage the tissues and organs by producing excessive amounts of ECM proteins. The persistent nature of an activated myofibroblast is maintained through molecular feedforward loops by autocrine and paracrine signaling and the influx of inflammatory cells [11, 12]. Reactive oxygen species (ROS) are one such signal that helps maintain the myofibroblast phenotype [13].

Ionizing radiation used in cancer therapy includes high-energy gamma rays and X-rays, which have sufficient energy to displace electrons from atoms. Interaction of these waves with water molecules leads to the excitation and ionization of water to form free radicals and ROS that include $e_{\text{aq}}^−$, hydroxyl radicals ($\cdot\text{OH}$), hydroperoxy radicals (HOO$^\cdot$), hydrogen peroxide (H$_2$O$_2$), and superoxide (O$_2^\cdot$) [13]. Generation of ROS also leads to an acute increase in oxidative stress within cells following radiation [14]. ROS can increase the levels and activity of several prooxidant enzymes, such as NADPH oxidases (NOXs), cyclooxygenases (COXs), nitric oxide synthases (NOSs), and lipoxygenases (LOXs) [15], which further promote ROS generation and the development of RIF. In addition to ROS, reactive nitrogen species (RNS), such as peroxynitrite (ONOO$^−$), are also generated and result in changes to signaling pathways, gene transcription, mitochondrial functioning, metabolism, and the chromatin architecture.

RIF is often observed in patients that have undergone radiation therapy for cancer treatment and persists long...
after the initial exposure to radiation [16]. RIF reduces the quality of life of patients after treatment [2–8], and there are no safe, approved therapies to mitigate this problem. Hence, the focus on understanding the ROS-mediated changes in chromatin-modifying proteins that lead to the development of RIF is essential. We will review the differences in expression and posttranslational modifications of chromatin regulators caused by ROS generated after radiation exposure. These changes could serve as biomarkers to estimate the severity and susceptibility of patients to develop RIF after radiation therapy. In some cases, epigenetic regulation has not been studied in the context of RIF. Therefore, we will review the reported changes in other fibrotic conditions. Lastly, we will discuss the potential of antioxidant drugs and epigenetic inhibitors used to prevent the development of RIF.

2. ROS-Mediated Metabolic Changes in RIF

The mitochondria are essential cell organelle involved in regulating both metabolism and ROS levels that impact the epigenome. Under normal metabolic conditions, the mitochondria produce low basal levels of superoxide via the electron transport chain, which is required for normal cellular signaling. Through normal metabolism, the mitochondria can also regulate the generation of epigenetic metabolites such as nicotinamide adenine dinucleotide (NAD), α-ketoglutarate (α-KG), S-adenosyl methionine (SAM), and acetyl-CoA. These molecules serve as cofactors for several epigenetic proteins and control epigenetic modifications such as DNA or histone methylation, histone acetylation, and ADP-ribosylation. Therefore, damage to the mitochondria can increase both levels of ROS and epigenetic metabolites, thereby promoting epigenetic alterations in the nucleus.

Ionizing radiation can directly damage mitochondrial DNA and nuclear DNA that codes for mitochondrial proteins, which leads to several functional changes in the mitochondrial structure, activity, and function [17–19]. Radiation exposure can result in excessive production of mitochondrial ROS due to an increase in mitochondrial abundance and loss in mitochondrial membrane integrity/potential [17, 20, 21]. Further, radiation-induced mitochondrial damage reduces production of the tricarboxylic acid (TCA) metabolites and causes a slight increase in fatty acid metabolism. Alteration of global metabolism and changes in the production of epigenetic metabolites or cofactors for chromatin-modifying proteins results in the modification of the fibroblast epigenome [22]. Also, antioxidant molecules, such as glutathione and NAD⁺, are significantly reduced following radiation and remain reduced for many hours following radiation exposure. As reported, many of the depleted metabolites are associated with oxidative stress and DNA repair pathways [23]. Thus, epigenetic changes in fibroblast cells and the development of RIF can be influenced by the changes in ROS and metabolism affected by damaged mitochondria as shown in Figure 1.

3. ROS-Mediated TGF-β Signaling Changes in RIF

The impact of ROS on TGF-β signaling is the most studied in the context of RIF [24–27]. An increase in ROS after radiation exposure leads to the activation of the TGF-β signaling pathway through the oxidation of cysteine residues of the latency-associated peptide (LAP). Oxidation of LAP leads to a conformational change in LAP, which allows the release of TGF-β from the latent complex. An active TGF-β, upon binding to TGF-β receptors, leads to the phosphorylation and activation of transcription factors, such as Smad2 and Smad3 [28]. As shown in Figure 1, it is known that ROS and TGF-β are interlinked by both feedforward and feedback mechanisms [25, 29]. TGF-β stimulation increases the basal level of ROS through several NADPH oxidases (NOXs), including NOX4, via the canonical Smad2/3 signaling factors [30] and activation of PI3K [28, 31]. Generation of ROS through NOX4 upregulation can also lead to the activation of the noncanonical Smad signaling pathway, which includes the activation of c-Src and FAK kinases [32]. These changes in the TGF-β signaling pathway can also cross-talk with the PI3K/AKT signaling pathway that leads to changes in the epigenome and the development of fibrosis.

4. ROS-Mediated DNA Methylation Changes in RIF

The covalent addition of methyl (CH₃) groups to DNA is controlled by DNA methyltransferases (DNMTs). In general, an increase in DNA methylation or hypermethylation of CpG islands at gene promoters is responsible for suppression of gene transcription. DNMTs can transfer methyl groups from SAM, and other methyl donors, to cytosines in DNA. The three enzymes involved in DNA methylation are DNMT1, DNMT3a, and DNMT3b. DNMT1 is a maintenance enzyme that copies methylation patterns onto an existing or new DNA strand following replication. DNMT3a and DNMT3b are classified as de novo DNMTs and are not dependent on preexisting methylation marks on DNA strands.

Aberrant DNA methylation is responsible for myofibroblast activation and changes in expression of fibrotic genes [32–34]. Changes in expression of DNMT1 [35, 36], DNMT3a [36, 37], and DNMT3b [36] have been identified in different models of fibrosis [38–40]. Upregulation of DNMT1 can be detected in fibrotic skin, kidneys, lungs, and liver tissues [32, 35, 41, 42]. Both DNMT1 and DNMT3a protein expression were found to be upregulated following 15 Gy irradiation of lung fibroblast cells [35]. This in vivo upregulation of DNMT1 and DNMT3a was observed at six weeks postradiation and was maintained up to six months following radiation exposure [35]. In contrast, fractionated low-dose radiation exposure leads to a small decrease in DNMT1 and DNMT3a expression, along with a reduction in methyl-CpG-binding protein MeCP2 [43]. This change in DNMT levels causes hypermethylation of antifibrotic genes: RASAL1 [44–50], PTC1 [34, 51] PPAR-γ [52], SOCS1/3 [53, 54], DKK1 [55], E-cadherin
Changes in the levels of DNA methyltransferases are closely associated with the TGF-β signaling pathway [32,40,44,70]. Alternatively, crosstalk of the TGF-β signaling pathway with the PI3K/Akt pathway can also increase DNMT expression via a transcription-independent mechanism involving an increase in phosphorylation and inactivation of glycogen synthase kinase-3β, leading to a decrease in ubiquitination of DNMT1 [32]. Increase in DNMT3α is attributed to an increase in protein translation due to the activation of the mammalian target of rapamycin complex 1 by Akt [32]. This reported mechanism has been studied in the context of activation and differentiation of fibroblast cells but not in the context of radiation exposure.

Inhibition of DNMTs using 5-aza-2′-deoxycytidine [37,64,71] or siRNA-mediated knockdown of DNMT1 expression prevents the activation of fibroblast cells and hepatic stellate cells [16,37] and protects against the development of fibrosis. This reduction in activated fibroblast cells is also associated with a reduction in ROS levels [72–74]. Moreover, the addition of hydrogen peroxide to embryonic lung fibroblasts rapidly increases DNMT levels [35]. Conversely, decreasing oxidative stress, using a superoxide scavenger Mn (III) TBAP [35], N-acetylcysteine [75], or L-NAME (NOS inhibitor) [75], resulted in decreased DNMT1 levels and loss of global DNA methylation. Therefore, it is suspected that superoxide and hydrogen peroxide are the ROS intermediates involved in the regulation of DNMT in RIF.

In certain cell types, such as cardiac fibroblast cells, stimulation with recombinant TGF-β leads to downregulation of DNMT1 and DNMT3α expression and inhibition in global DNMT activity [76]. This has been linked to a decrease in DNA methylation at the promoter of COL1A1 and an increase in the expression of COL1A1 mRNA [76]. Therefore, changes in expression of DNMT proteins and changes in DNA methylation by the direct activation of the TGF-β signaling pathway or indirect activation through radiation and ROS can be variable and dependent on the tissue and organ under investigation.

Along with an increase in levels of DNMTs, an increase in the methylated DNA-binding protein, MeCP2, is also observed during fibrosis [77,78]. Binding of MeCP2 to methylated CpG regions causes transcriptional repression. Similar to DNMT1, expression levels of MeCP2 are sensitive to changes in oxidative stress and redox balance [79–82]. It is believed that MeCP2 levels increase to maintain DNA methylation by the formation of DNMT1-MeCP2 complexes in an increasingly oxidative environment of fibrosis [83,84]. Fractionated low-dose radiation exposure has been reported to cause an increase in MeCP2 in the brain [85] and downregulation in the spleen [86] and thymus [43]. Upregulation of MeCP2 was found to be associated with downregulation of profibrotic genes, such as PPAR-γ [87], RASAL1 [88], and PTCH1 [34,88], thereby promoting myofibroblast differentiation and the development of fibrosis [87].
Some of the DNA methylation changes at specific gene promoters may be independent of changes in the expression of DNMTs. This is because it is suggested that superoxide is a strong anion that can participate in nucleophilic substitutions and free radical abstraction, leading to changes in DNA methylation and histone modifications. Superoxide neutralizes positive charges of methyl donors, SAM, and acetyl-CoA, which can then deprotonate the cytosine molecule at the C-5 position and accelerate the reaction of DNA with SAM; thereby, causing methylation of DNA [89, 90]. However, this has not been tested in the context of fibrosis.

In summary, increased oxidative stress after radiation is intimately interconnected with increased DNMT levels, activity, and DNA methylation. Activation of the TGF-β signaling pathway by ROS mechanistically drives the sustained high levels of DNMTs. Further, changes in interaction with binding partners (MeCP2, HMTs, and HDACs) and cofactors (SAM) can lead to changes in DNMT levels and DNA methylation at specific gene promoters. Targeting DNMTs, the TGF-β signaling pathway, or oxidative stress has been shown to modulate DNA methylation and reduce fibrosis. However, large-scale genome-wide DNA methylation studies are needed to delineate hypomethylation and hypermethylation status at different gene promoters during RIF.

5. ROS-Mediated Histone Modification

Changes in RIF

Histones can be modified through covalent posttranslational modifications (PTMs) that control the open or closed architecture of the chromatin for gene expression. These modifications include methylation, acetylation, phosphorylation, ubiquitination, and sumoylation. Changes in histone modifications have been associated with altered expression of profibrotic and antifibrotic genes that lead to fibrosis. Furthermore, changes in the expression of microRNAs have also been associated with histone modifications and fibrotic gene expression. PTMs such as histone acetylation and histone methylation marks are redox sensitive and are inherited by daughter cells in RIF.

5.1. Role of Histone Acetylation in RIF

Histone acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). The balance between the epigenetic marks added by HATs and removed by HDACs helps to control gene transcription. In general, acetylated histones are associated with transcriptionally active chromatin and deacetylated histones with inactive chromatin [87].

HATs are enzymes that catalyze the transfer of an acetyl group from acetyl-CoA to the ε-amino group of histone lysine residues. Out of the 30 known HAT enzymes, only EP300 (p300) and CREBBP (CBP) have been reported to play a role in RIF [91]. Levels of p300/CBP were found to be significantly elevated in skin fibroblast cells 12 hours after radiation exposure but not after 24 or 36 hours [91]. This increase in p300/CBP also correlated with an increase in alpha-smooth muscle actin (αSMA), which is a marker for myofibroblast cells.

The mechanism of p300/CBP upregulation and/or increased activity is also linked to an active TGF-β/ROS signaling pathway [91–100]. p300 is a direct transcriptional target of TGF-β signaling and is known to form a feedforward loop with an active TGF-β signaling pathway [101–103]. Interaction of p300 with Smad3 is essential for the TGF-β-mediated synthesis of collagen [101]. Also, inhibition of p300 expression or activity reduces fibrosis [96, 100, 104–107]. The role of p300 in fibroblast biology and fibrosis has been studied by Ghosh et al., and the targeted disruption of p300-mediated histone acetylation has been proposed as a viable antifibrotic strategy [101].

The redox environment can directly alter the activity of p300 due to the oxidation of key cysteine residues. Specifically, the oxidation of these thiols results in reduced p300 activity. Redox-active compounds such as MnTE-2-PyP and hydroxynaphthoquinones can downregulate p300 activity [108–111]. The use of alpha-lipoic acid, a dietary antioxidant supplement, has been shown to protect against RIF in mice by downregulating expression and activity of p300/CBP [112–115]. Similarly, inhibition of p300 activity using curcumin also reduces cardiac fibrosis and hypertrophy [32, 94, 116]. However, thiol oxidation of p300 during RIF has not been studied.

Both p300 and CBP have high sequence homology and can act as transcriptional coactivators, which recruit basal transcriptional machinery, including RNA polymerase II, to gene promoters. p300 and CBP promote the transcription of fibrotic genes, such as matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9), αSMA, and plasminogen activator inhibitor-1 (PAI-1) [91] in this manner. Moreover, increased histone acetylation at the H3K9/14 and H3K18 marks has been associated with an upregulation of TGF-β1, TGF-β3, and another potent profibrotic factor, connective tissue growth factor (CTGF) [117].

During fibrosis, an increase in histone acetylation can also be mediated by an increase in activity of ATP citrate lyase (ACL), an enzyme that converts citrate to acetyl-CoA, which is a substrate for HATs [117]. Thus, histone acetylation is affected by changes in glucose metabolism and oxidative stress during fibrosis [118, 119]. Correspondingly, high-glucose treatment can increase oxidative stress and increase pan-H3 histone acetylation marks [108, 120]. However, this process has not been studied in the context of RIF.

In summary, histone acetylation in RIF is attributed to an increase in the level of expression and activity of HAT enzymes, p300 and CBP. HAT expression is further upregulated by the TGF-β signaling pathway. Antioxidants have been shown to inhibit HAT activity and prevent the development of fibrosis. However, the mechanism of inhibition of HAT activity by antioxidants has not been determined in the context of RIF. Other studies, unrelated to fibrosis, point towards susceptibility of p300 to several PTMs that are influenced by a change in the oxidative environment [101, 108, 121, 122].
5.2. Role of Histone Deacetylation in RIF. HDACs are a class of enzymes that compress the chromatin by removing acetyl groups, which results in a downregulation in gene expression. There are a total of 11 known HDACs that are dependent on the cofactor, Zn$^{2+}$, to deacetylate histones. Another class of enzymes known as sirtuins (Sirt) contains seven members that deacetylate histones and are dependent on NAD$^+$ as a cofactor.

Upregulation of several HDAC enzymes is known to be involved in the development of fibrosis [123–131]. Profibrotic stimulation, using TGF-β or the platelet-derived growth factor (PDGF), upregulates the expression of HDAC1, HDAC2, and HDAC4, which results in fibrosis of a variety of tissues [124, 125, 132]. Also, all three HDAC proteins involved in fibrosis are redox sensitive. Upregulation of certain HDACs can lead to the deacetylation of histones associated with antifibrotic genes and downregulation of genes that prevent the development of fibrosis. Hence, HDAC proteins are reported to be potential targets for fibrotic disorders [133]. However, the role of HDAC proteins and HDAC inhibitors in RIF has not been studied.

HDAC1, a well-known epigenetic and cell cycle regulator, is redox sensitive and plays a crucial role in normal development and tumor progression [134, 135]. During fibrosis, HDAC1 upregulation causes epithelial-mesenchymal transition by suppressing the transcription of ZO-1 and E-cadherin [124]. In addition, HDAC1 promotes fibrosis by inhibiting the expression of the antifibrotic Smad7 protein in renal fibrosis [95]. In agreement with this finding, the HDAC inhibitor, suberoylanilide hydroxamic acid, was successful in stabilizing Smad7 levels, thereby preventing fibroblast differentiation and collagen expression in a lung fibrosis model in rats [123].

Similarly, HDAC4 upregulation enhances the expression of profibrotic genes in lung fibrosis [136, 137] and causes transdifferentiation of hepatic stellate cells to myofibroblast cells [138]. Knockdown of HDAC4 inhibits fibrosis by reversing the TGF-β-stimulated transformation of fibroblasts to myofibroblasts [139]. HDAC4 is a redox-sensitive protein, where oxidation of Cys$^{667}$ and Cys$^{669}$ affects its activity and is independent of other phosphorylation modifications [140, 141]. Specifically, reduction of these two cysteine residues has also been shown to prevent its nuclear export [141].

In liver fibrosis, HDAC2 was found to be upregulated, which activates hepatic stellate cells through the suppression of the antifibrotic protein, Smad7 [142]. Moreover, HDAC2 and DNMT1 have been suggested to cooperate in adding repressive chromatin marks at gene promoters to suppress the expression of antifibrotic genes, such as RASAL1 [46, 143]. Oxidative stress causes tyrosine nitration of HDAC2, thereby reducing its activity [144]. These PTMs are prevented with the use of antioxidants, such as glutathione monoethyl ester or polyphenol-curcumin [145, 146]. Overexpression of SOD2 decreases HDAC2 expression due to an increase in ubiquitination of HDAC2 molecules [147]. Therefore, a change in expression and activity of HDAC2 is highly regulated by the redox environment [148–151].

Reduction in HDAC1/2 expression using gallic acid or valproic acid sodium (VPA) attenuates hypertension, cardiac remodeling, and fibrosis in mice [152]. RNS, such as nitric oxide, has an inhibitory effect on HDAC activity resulting in the hyperacetylation of specific genes [153]. The inhibitory effects of RNS on HDAC proteins are associated with nitrosylation of tyrosine residues and aldehyde-adduct formation on HDAC1, HDAC2, and HDAC3 proteins [145]. As mentioned previously, PTMs of HDACs due to oxidative modification of conserved cysteine residues have also been linked to nuclear export [154]. However, these changes mediated by RNS have not been studied extensively in the context of RIF.

HDAC inhibitor (HDACi) drugs, romidepsin [155], trichostatin A [156, 157], suberoylanilide hydroxamic acid [123, 158], sodium valproate [159], panobinostat [160, 161], and valproic acid [162, 163], have all been shown to suppress fibrosis. In a standard animal model of cutaneous radiation syndrome, application of topical formulations of phenylbutyrate, an HDACi [164] and oxidative stress inhibitor [165–167], reduced acute skin damage and protected from late radiation-induced effects, such as fibrosis and tumor formation [168]. This reduction in RIF after HDAC inhibition further correlated with suppression of TGF-β and TNF-α signaling [168]. Therefore, HDAC inhibitors have been used and are proposed as radioprotectors for treating RIF [168]. However, the potential nonspecificity of these broad inhibitors may produce many unwanted side effects, making these drugs potentially unsuitable for therapeutic use.

In summary, HDACs are upregulated during radiation and are associated with fibrosis but vary with the tissue type and radiation dose. The majority of upregulated HDAC proteins during fibrosis can be countered with the use of either HDACi or antioxidants. Some changes in PTMs of HDAC proteins due to oxidative stress have been associated with changes in HDAC activity but have not been studied in the context of RIF.

5.3. Role of Sirtuin Deacetylases in RIF. Sirtuin proteins are deacetylase enzymes that are redox sensitive because they require NAD$^+$ as a cofactor to be active. As mentioned above, radiation-associated damage to the mitochondria can alter levels of NAD$^+$, which can change the activity of sirtuin proteins. These enzymes are involved in the deacetylation of both histone and nonhistone proteins depending on their localization. Sirt1, Sirt6, and Sirt7 localize to and exert distinct deacetylation functions in the nucleus [169], while Sirt3, Sirt4, and Sirt5 localize to the mitochondria [170] and are indirectly involved in epigenetic reprogramming during fibrosis and are involved in the modulation of oxidative stress by regulating mitochondrial antioxidant proteins and cellular metabolism.

In contrast to HDACs, Sirt1 overexpression or upregulation protects against fibrosis by attenuating the TGF-β and NF-κB signaling pathways [32, 92, 171–180]. Moreover, Sirt1 is a negative regulator of p300 expression [92, 181]. Ionizing radiation, cigarette smoke extract, and carbon tetra-chloride increase oxidative stress and downregulate Sirt1
gene expression [32, 182, 183]. Nonionizing radiation, such as UV irradiation, also decreases Sirt1 activity [184], which may result in fibrosis. This change in Sirt1 activity needs to be further investigated in relation to the cellular NAD⁺ levels [184] and oxidative stress-dependent NAD⁺ metabolism [185] during fibrosis. The decrease in Sirt1 expression, activity, and changes in its subcellular localization can be linked to changes in Sirt1-catalyzed PTMs influenced by oxidative stress [32, 148, 186–189]. Treatment of fibroblast cells with H₂O₂ downregulates Sirt1 levels [190], while the use of antioxidants such as resveratrol [191–197], curcumin [198], phentolamine [182], and vitamin D [199, 200] has been shown to upregulate Sirt1 expression after radiation.

To combat and repair the cell from radiation-induced oxidative damage, fibroblast cells upregulate and/or increase the activity of Sirt1 [171, 172, 192, 201–203]. Sirt1 knockdown and overexpression have been shown to alter ROS levels within a variety of cell types [203–207]. Sirt1 is involved in deacetylation of histones, specifically the removal of H3K9Ac, H3K14Ac, H4K16Ac, and H1K26Ac marks, which leads to an upregulation of antioxidant genes such as superoxide dismutase (SOD) [148]. Further, deacetylation of transcriptional factors such as the nuclear factor erythroid-related factor (Nrf), Nrf1 or Nrf2 [208, 209], and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC1-α) [174, 176, 178, 210–212] is also involved in controlling the expression of SOD. The Nrf2 transcription factor is a crucial regulator of the antioxidant defense pathway and has been reported to inhibit the TGF-β signaling pathway [208]. Therefore, Sirt1 is a redox sensor that acts as an antibacterial protein via deacetylation of both histones and nonhistone proteins.

Similarly, Sirt3, Sirt6, and Sirt7 are all redox-sensitive proteins and modulate oxidative stress in fibrotic tissues. Sirt3 upregulation has a protective effect against radiation-induced lung injury by exerting anti-inflammatory and antioxidative properties [213–215]. Further, Sirt3 is responsible for preventing epithelial-mesenchymal transition (EMT) by elevating the levels of Nrf2 and PGC1-α expression [216, 217]. In parallel to this, Sirt3 deficiency has been shown to promote lung fibrosis [214] and its activity is required to deacetylate and activate MsnSOD. An active MsnSOD enzyme is necessary to detoxify mitochondrial ROS and prevent mtDNA damage [214]. Sirt6 overexpression prevents hepatic fibrosis by curbing inflammation and oxidative stress [218], and Sirt6 deficiency results in progressive renal inflammation and fibrosis [219]. Moreover, it is known that Sirt6 exhibits an inhibitory effect on the activity of TGF-β [220] and NF-κB signaling [221] that are activated in RIF. In addition, a decrease in expression of Sirt7 is associated with the development of lung fibrosis [222, 223] and fibroblast differentiation in cardiac tissue [216].

Paradoxically, Sirt2 and Sirt4 downregulation prevents fibrosis and is also modulated by treatment of antioxidant molecules [224, 225]. Sirt2 potentiates radiation-induced damage in fibroblast cells by interacting with β-catenin and, thereby, inhibiting Wnt signaling [226]. Inhibiting Sirt2 activity prevents transformation and preserves the integrity of aging fibroblast cells against ROS [226]. However, in the brain, Sirt2 has been shown to be essential in preventing neurotoxicity and cognitive dysfunction after whole brain radiation [227] and plays a role in preventing neuroinflammation and brain injury [228]. Sirt4 is involved in the development of cardiac fibrosis after angiotensin II treatment and is involved in the regulation of oxidative stress [229]. Treatment with a SOD mimetic, 5, 10, 15, and 20-tetrakis-(4-benzoic acid) porphyrin, inhibited ROS accumulation and Sirt4-mediated development of cardiac fibrosis [229].

In contrast to the upregulation of HDAC proteins, upregulation of most sirtuins protects from RIF development. The upregulation and increase in activity of sirtuins combat radiation-induced oxidative stress and counterbalance the increase in expression of HAT enzymes and radiation-induced epigenetic modifications. Like HATs, increase in sirtuin protein levels or activity occurs through acute changes in signaling pathways, redox environment, and metabolite production after radiation. The protective effects of sirtuin proteins are thought to be mediated, in part, by deacetylating histones and key transcription factors involved in the antioxidant pathway, such as Nrf2 and PGC1-α.

5.4. Role of Histone Methylation in RIF. Histone methylation can either increase or decrease transcription of genes depending on the amino acid methylated (lysine or arginine), position on the histone tail, and the number of methyl groups added. This dynamic process is regulated by more than 40 histone methyltransferases (HMTs) and demethylases, which are involved in the establishment of a histone methylome. For these reasons, specific histone methylation alterations have not been studied in the context of radiation. However, reports indicate that histone methylation plays a critical role in fibrotic gene expression and fibrosis [230]. TGF-β stimulation increases the expression of EZH2, SET7 [231], SET9 [231], and G9a [232]. Furthermore, an active TGF-β pathway has been linked to an increase in H3K4Me1, H3K4Me2, and H3K4Me3 (active chromatin marks) and a decrease in H3K9Me2 and H3K9Me3 (repressive chromatin marks) at profibrotic gene promoters [230, 231, 233, 234]. Among the several HMTs, EZH2 was shown to be upregulated during the differentiation of fibroblasts to myofibroblasts in the lungs of patients with idiopathic pulmonary fibrosis [235]. Induction of EZH2 expression after TGF-β stimulation can lead to an increase in H3K27Me3 (repressive marks) at COX-2 gene promoters (antibiotic gene), which promotes fibrosis [236, 237]. This increase in EZH2 expression also correlates with an increase in the expression of ECM proteins, such as COL3A1 [233]. Importantly, antibacterial genes, such as Caveolin-1 [238], are exclusively regulated by histone methylation [239] and not by DNA methylation. Further, EZH2 forms repression complexes with MeCP2 and SIN3A, transcriptional repressors, which can suppress the expression of antibacterial genes [87, 240]. Treatment of epithelial cells with H₂O₂ causes the translocation of EZH2 from the nucleus to the cytoplasm by regulating its phosphorylation status [241]. Inhibition of HMTs, using 3-deazaadenosine A (DZNep), suppressed the progression of renal and pulmonary fibrosis [242, 243].
Further, inhibition of the TGF-β and TNF-α signaling pathways using a novel indole compound, MA-35, resulted in the attenuation of renal inflammation and fibrosis by decreasing H3K4me1 histone modification at the COL1A1 and PAI-1 fibrotic gene promoters [244]. Inhibition of H3K9me1 using BIX01294, an inhibitor of G9a methyltransferase, prevented the development of renal fibrosis by maintaining expression of the antifibrotic gene, Klotho [232]. Therefore, an active TGF-β pathway, due to the generation of ROS after radiation, can lead to an upregulation of these HMTs leading to the development of RIF [232].

Activation of hepatic stellate cells (HSC), by bile duct ligation procedure, leads to transdifferentiation of HSC to a myofibroblast-like phenotype [245]. This transdifferentiation is associated with an increase in HMTs such as KMT2H (aka ASH1), KMT1A (aka SUV39H1), KMT1B (aka SUV39H2), KMT1D (aka GLP), KMT6 (aka EZH2), KMT3C (aka Smyd2), KMT2A (aka MLL1), KMT2E (aka MLL5), and KMT2F (aka SET1A) and a compensatory increase in histone demethylases (HDMs) such as KDM1 (aka LSD1), KDM5B (aka JARID1b), KDM4A (aka JMJD2a), and KDM4B (aka JMJD2b) [245]. This is also associated with the upregulation of profibrotic genes, such as αSMA, TIMP-1, collagen I, and TGF-β. Several of these histone enzymes are activated and inhibited by metabolic cofactors that are considered redox intermediates such as NAD+, SAM, flavin adenine dinucleotide (FAD), and 2-oxoglutarate. Further, the jumonji domain-containing (jmjC) family of proteins, which is involved in histone demethylation, is highly redox sensitive due to the presence of a transition metal, iron (Fe), at the enzyme active site. Fe (II) is used as a cofactor for the histone demethylation reaction and can interact with H2O2 to produce ·OH, leading to an increase in oxidative damage and histone methylation [246, 247]. Changes in the redox environment have also been reported to increase the activity of LSD1, which is involved in DNA repair after oxidative damage [248]. HDMs, such as KDM6B, can be induced by the TGF-β pathway and promote EMT transition during fibrosis [249], which can also have implications in the context of RIF. However, the role of these histone methylation-regulating proteins has not been extensively studied in the context of changing oxidative stress and fibrosis.

6. ROS-Mediated Noncoding RNA Changes in RIF

Noncoding RNAs that regulate epigenetic processes in RIF include, micro-RNAs (miRs), long noncoding RNA (lncRNA), and circular RNA (circRNA). miRs are considered to play an essential role in regulating the epigenome and are modulated by changes in oxidative stress during radiation exposure [26, 250]. Further, expression of miRs is interconnected with the TGF-β signaling pathway [16, 36, 132, 250–259]. DROSHA and DICER regulate the biogenesis of the majority of miRs in healthy cells and are involved in radiation damage responses due, in part, to the production of ROS [260]. Increase in ROS inactivates DROSHA and DICER, which impairs DNA damage responses in human fibroblasts after radiation [261]. TGF-β signaling pathway proteins, p-Smad-2 and p-Smad-3, have been shown to interact with DROSHA and DICER to regulate the processing of miR-21 in cardiac fibroblasts [262, 263]. Mature miR-21 has been implicated in the development of RIF in several tissues [264–267]. In endothelial cells, H2O2 treatment downregulates the expression of DICER [268–270]. However, in hepatic stellate cells (HSC), inhibition of DICER suppresses HSC activation as well as ECM expression [271]. It is unknown if ROS are directly involved in PTMs of DROSHA and DICER activity. However, downregulation of DICER prevents the generation of ROS by lowering expression of the p47phox protein, which is a part of the NOX2 complex that generates ROS [272]. Therefore, there exists a close relationship between the miR-processing proteins, an active TGF-β signaling pathway, and ROS that needs to be further investigated in the context of RIF.

Following radiation, ten miR species have been found to be upregulated: let-7d, let-7g, let-7i, miR-26b, miR-663, let-7e, miR-15b, miR-21, miR-768-3p, and miR-768-5p. Seven miRs were found to be downregulated: miR-24, let-7a, miR-100, miR-125b, miR-222, let-7b, and miR-638 in normal human fibroblasts [250]. Out of these 17 miRs, changes in intracellular levels of hydrogen peroxide have been associated with altered expression of let-7d, let-7b, let-7e, miR-15b, miR-768-3p, miR-768-5p, miR-24, miR-21, and miR-638. Some miRs such as the miR-29 family members are not directly regulated by changes in ROS and are dependent on the TGF-β signaling pathway. MiR-29 family members are downregulated after radiation, which leads to an increase in expression of type I collagen genes that contribute to the development of RIF [273]. Further, loss of radioprotective miR-140 is observed in human lung fibroblasts, which is known to regulate the TGF-β signaling pathway and expression of fibronectin [274]. These miRs could potentially drive acute and chronic changes in molecular connections to combat oxidative stress during fibrosis [275].

Treatment with a thiol antioxidant, cysteine, prevents changes in the expression of some of the above miRs initiated by ionizing radiation [250]. The potential to regulate miR expression using locked nucleic acid- (LNA-) modified anti-miR inhibitors in combination with antioxidants is an attractive avenue for prevention of RIF [264]. Moreover, these miRs can be used as potential biomarkers for patients at risk of developing RIF [276–279].

Apart from miRs, other noncoding RNAs such as lncRNA, which are >200 nucleotides [280], and circRNA [281, 282] have also been shown to be dysregulated in RIF. IncRNAs play a role in epigenetic regulation by forming complexes with chromatin-modifying proteins. However, these RNA molecules have not been extensively studied in the context of changing oxidative stress. In normal human bronchial epithelial cells, overexpression of long intergenic radiation-responsive RNAs (LIRRs), noncoding RNAs, increased radiosensitivity through a DNA damage response (DDR) signaling mechanism that is p53 dependent [280]. Similarly, Inc-R1 is a radiation-inducible lncRNA molecule involved in radiation-induced DDR [283]. In hepatic stellate cells, 179 circRNAs were found to be upregulated and 630 circRNAs were downregulated after irradiation [281].
Inhibition of hsa-circ-0071410 has been shown to attenuate radiation-induced hepatic stellate cell activation [281]. Two other circRNAs, KIRKOS-73 and KIRKOS-71, are upregulated following radiation exposure and can serve as diagnostic radiotherapy biomarkers [282]. However, the role of these noncoding RNAs have not been studied in the context of ROS-mediated development of RIF. We do not know whether the use of antioxidants influences the expression of these molecules.

7. Conclusion

Radiation therapy leads to the development of RIF and decreases the overall quality of life of irradiated cancer
Table 1: Antioxidants/antifibrotic agents used to prevent radiation-induced damage and fibrosis.

| Antioxidant/antifibrotic agents | Region                  | Radiation dose/animals | Dose                        | Effects                                                                 | Reference |
|---------------------------------|-------------------------|------------------------|-----------------------------|-------------------------------------------------------------------------|-----------|
| AEOL 10150 (catalytic SOD mimic) | Lung                    | 28 Gy/rats             | 10-30 mg/kg/day, for 10 weeks | Inhibits TGF-β signaling                                                 | [291]     |
|                                 | Small intestine         | 15 Gy/mice             | 100 mg/kg, 3 days before radiation | Reduces inflammation and cell death and reduces p-NF-κB, MMP9, and MAPK signaling and facilitates regeneration of vitamins C and E and elevates glutathione levels | [293]     |
| Alpha-lipoic acid               | Thyroid                 | 18 Gy/rats             | 100 mg/kg, 24 h before radiation | Inhibits TGF-β signaling                                                | [115]     |
|                                 | Salivary gland          | 18 Gy/rats             | 100 mg/kg, 24 h before irradiation | Reduces oxidative stress by inhibiting gr91 mRNA expression            | [294]     |
|                                 | Head and neck           | 20–70 Gy/humans        | 200 mg/m² to 400 mg/m²      | Thiol compound and free radical scavenger; reduces oxidative radicals and prevents xerostomia (dry mouth) postirradiation. | [295, 296]|
| Amifostine (WR-2721)            | Heart                   | 22.5 Gy/rats           | 160 mg/kg, 15 minutes before radiation | Reduces cardiac damage                                                 | [297]     |
|                                 | Heart                   | 18 Gy/mice             | 200 mg/kg, 30 minutes before radiation | Prevents vasculitis and vascular injury                               | [298]     |
|                                 | Kidney                  | 15 Gy                  | 200 mg/kg, 30 minutes before radiation | Prevents glomerular and tubular changes and interstitial fibrotic lesions postradiation | [299, 300]|
| Atorvastatin                    | Kidney                  | 2 Gy/mice              | 50 mg/kg/day for 1 week     | Reduces the levels of oxidative stress markers                         | [301]     |
| CpG oligodeoxynucleotide        | Lung                    | 15 Gy/mice             | 50 μg CpG-ODN               | Prevents radiation-induced pulmonary fibrosis by shifting the imbalance of Th1 and Th2 responses | [302]     |
|                                 | Lung                    | 18 Gy/rats             | 200 mg/kg/day, 1 week before radiation | Boosts antioxidant defenses by increasing HO-1, prevents COX-2 upregulation, and inhibits proinflammatory cytokines and NF-κB signaling and prevents LPS-induced TNF-α production | [303]     |
| Curcumin                        | Lung                    | 13.5 Gy/mice           | 1% or 5% (w/w)              | Prevents radiation-induced pulmonary fibrosis and reduces LPS-induced TNF-α production | [304]     |
| Erdosteine                      | Whole body/kidney       | 5 Gy/rats              | 100 mg/kg/day, 1 week before irradiation by gastric tube | Inhibits production of proinflammatory cytokines TNF-α, IL-1, IFNγ, and IL-6 | [305]     |
| Eukarion-189 (catalytic SOD catalase mimic) | Lung | 10 to 20.5 Gy/rats | 30 mg/kg, 30 minutes before radiation | Inhibits TGF-β signaling                                              | [306]     |
| Eukarion-207 (catalytic SOD catalase mimic) | Lung | 12 Gy/rats | 8 mg/kg/day | Reduces oxidative damage, TGF-β, and NF-κB signaling and activated macrophages | [307]     |
| Antioxidant/antifibrotic agents | Region | Radiation dose/animals | Dose | Effects | Reference |
|-------------------------------|-------|-----------------------|------|---------|-----------|
| **Flaxseed**                  | Lung  | 13.5 Gy/mice          | 10% (w/w) | Reduces expression of lung injury biomarkers (Bax, p21, and TGF-β) and contains omega-3 fatty acids and lignans with antioxidant properties | [308] |
| **Follistatin**               | Hindlimb | 35 Gy/mice            | 4 μg, 24 hours before, 2 days after radiation, and then 3/week over 6 months | Inhibits TGF-β signaling | [285] |
| **GC4401**                   | Whole body/liver | 2 × 2 Gy/mice       | 2 mg/kg before every fraction | Protects the liver in Sirt3−/− animals from radiation-induced injury | [309] |
| **GC4419**                   | Oral cavity | 60 to 72 Gy/humans | 15 to 112 mg/day, 60 min before radiation for 3 to 7 weeks | Reduces the frequency and duration of oral mucositis | [310] |
| **Genistein (isoflavone)**   | Lung  | 12 Gy/rats            | 50 mg/kg/day | Reduces oxidative damage, TGF-β, and NF-xb signaling and activated macrophages and fibrosis | [307] |
| **Ginger extract**           | Kidney | 2, 4, and 8 Gy/rats   | 50 mg/kg/day for 10 days | Alleviates functional and structural alterations in the kidney due to antioxidant and anti-inflammatory effects | [311] |
| **Gingko biloba**            | Whole body | 8 Gy/rats             | 50 mg/kg/day, 15-day pretreatment | Attenuates irradiation-induced oxidative organ injury, by preventing an increase in LDH and TNF-alpha levels | [312] |
|                              | Eye    | 5 Gy/rats             | 40 mg/kg/day, 3 days pretreatment and up to 7 days postradiation | Prevents increase in xanthine oxidase (XO) activity postradiation | [313] |
|                              | Whole body | 6 Gy/rats             | 50 and 100 mg/kg/day for 7 days | Corrects the metabolic disturbances induced in the brain by lowering dopamine, calcium, and zinc contents while increasing iron content and restores the activities of lactate dehydrogenase and cholinesterase enzymes | [314] |
| **GTS-21 (α7-nAChR agonist)** | Lung  | 12 Gy/mice            | 4 mg/kg/day | Reduces TNF-α, IL-1β, and IL-6 production in serum via inhibition of NF-xB and downregulates TLR-4 and HMGB1 expression in the lungs and reduces ROS levels and HIF-1α expression along with inhibition of NOX1 and NOX2 expression | [315] |
| **Hesperidin**               | Heart  | 18 Gy/rats            | 100 mg/kg/day for 7 days | Decreases inflammation, fibrosis, mast cell and macrophage numbers, and myocyte necrosis after radiation | [316] |
| Antioxidant/antifibrotic agents | Region | Radiation dose/animals | Dose | Effects | Reference |
|---------------------------------|--------|------------------------|------|---------|-----------|
| JP4-039 (TEMPOL) | Skin/leg | 35 Gy/mice | 50 μL of formulation, 0.5, 24, and 48 h after radiation | Reduces radiation-induced skin damage | [317] |
| KL4 surfactant (21-amino acid peptide) | Lung | 13.5 Gy/mice | 120 mg/kg twice daily | Reduces lung inflammation and oxidative stress | [318] |
| Matrine (alkaloid) | Whole body | 6-7 Gy/rats | 30, 10, and 3 mg/kg/day, 3 days before or after radiation | Reduces radiation-induced damage by altering 21 pathways | [319] |
| Melatonin | Lung | 18 Gy/rats | 100 mg/kg once 30 minutes before radiation | Reduces lipid peroxidation product malondialdehyde | [320] |
| MnTnHex-2-PyP (catalytic SOD mimic) | Lung | 28 Gy/rats | 0.05 mg/kg/day for 2 weeks, 2 h postradiation | Inhibits TGF-β signaling and protects against decreases in RBC counts, hemoglobin, and hematocrit | [321] |
| MnTnHex-2-PyP (catalytic SOD mimic) | Lung | 28 Gy/rats | 0.05 mg/kg twice daily for 2 months | Prevents radiation injury in the lungs | [322] |
| Prostate | 10 Gy/mice | 6 mg/kg/day, day 1 to 16 | | | |
| Pelvic region | 20-30 Gy/rats | 5 mg/kg/week, 1 h before radiation | | Ameliorates both acute and chronic radiation proctitis | [323] |
| MnTE-2-PyP Or AEOL 10113 (catalytic SOD mimic) | Pelvic region | 37.5 Gy/mice | 10 mg/kg/week, 24 h before radiation; for the first two weeks, 3 times/week at a dose of 5 mg/kg | | [324] |
| MnTE-2-PyP Or AEOL 10113 (catalytic SOD mimic) | Lung | 28 Gy/rats | 6 mg/kg/day, 15 min before radiation | Inhibits TGF-β signaling | [325] |
| MnTE-2-PyP Or AEOL 10113 (catalytic SOD mimic) | Lung | 28 Gy/rats | 6 mg/kg/day for 10 weeks | Decreases HIF-1alpha, TGF-β, and VEGF A expression after radiation | [326] |
| Brain | 5 Gy/mice | 1.5 mg/kg, twice daily, for 14 days | Protects hippocampal neurogenesis | | [327, 328] |
| Brain | 8 Gy/mice | 1.6 mg/kg, twice daily, 24 h before radiation | Protects the brain from negative effects of cranial irradiation | | [327, 328] |
| Colon | 2 Gy/mice | 0.25 μM every 3 days, in vitro studies | Prevents activation and increase in cell size of fibroblast cells from the colon | | [329] |
| Whole body | 18 Gy/mice | 500 mg/kg/day, 3 days before and up to 3 days postradiation | Protects the lung and red blood cells from glutathione depletion following irradiation | | [329] |
| Whole body | 6 Gy/rats | 1000 mg/kg, 15 min before radiation | Protects rat femoral bone marrow cells from radiation-induced genotoxicity and cytotoxicity | | [330] |
| N-Acetyl cysteine (NAC) | Abdomen | 10 Gy/rats | 300 mg/kg/day | Alleviates the negative effects of radiotherapy on incisional wound healing by means of reducing oxidative stress markers | [331] |
| Antioxidant/antifibrotic agents | Region | Radiation dose/animals | Dose | Effects | Reference |
|--------------------------------|--------|------------------------|------|---------|-----------|
| Abdomen                        | 20 Gy/mice | 300 mg/kg/day, for 7 days | Prevents gastrointestinal injury, damage to bone marrow stromal cells, and radiation-induced acute death | [326] |
| Plasminogen activator inhibitor-1 (PAI-1) truncated | Lung | 30 Gy/mice | 5.4 μg/kg/day for 18 weeks beginning 2 days before radiation | Prevents RIF with increased fibrin metabolism, enhanced matrix metalloproteinase-3 expression, and reduced senescence in type 2 pneumocytes | [332] |
| Plasminogen activator inhibitor-1 (PAI-1) truncated | Lung | 16 Gy/mice | 300 mg/kg/day for four weeks | Inhibits TGF-β signaling | [333] |
| Pirfenidone                    | Intestine | 20 Gy/mice | 200 and 400 mg/kg/day for 12 weeks | Inhibits TGF-β signaling | [334] |
| Head and neck                  | 60-72 Gy/humans | 800 mg three times/day | — | [335] |
| Podophyllotoxin and rutin combination (G-003M) | Lung | 11 Gy/mice | 5 mg/kg once | Reduces radiation-induced oxidative and inflammatory stress | [336] |
| Polydatin                      | Lung | 15 Gy/mice | 100 mg/kg/day | Exerts anti-inflammation and antioxidative properties through Nrf2 signaling and Sirt3 upregulation | [213] |
| Quercetin                      | Intestine | 13 Gy/mice | 100 mg/kg/day for 6 days before and after radiation | Inhibits TGF-β signaling | [337] |
| Skin/hind leg                  | 35 Gy and 10 Gy/mice | Quercetin-formulated chow (1% by weight) | [338] |
| Resveratrol                    | Whole body | 3 Gy/mice | 100 mg/kg/day, 2 days pretreatment and up to 30 days | Reduces radiation-induced chromosome aberration frequencies | [340] |
| Salivary gland                 | 15 Gy/mice | 20 mg/kg/day | Inhibits TGF-β signaling and protects the salivary glands against the negative effects of irradiation | [341] |
| Ovary                          | 21 Gy/rats | 25 mg/kg/day for 2 weeks | Counteracts the effect of radiation and upregulates the gene expression of PPAR-γ and Sirt1, leading to inhibition of NF-κB-provoked inflammatory cytokines | [191, 342] |
| Antioxidant/antifibrotic agents | Region                          | Radiation dose/animals | Dose                                      | Effects                                                                                       | Reference |
|--------------------------------|--------------------------------|------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------|-----------|
|                                | Whole body/hematopoietic stem cell | 6 Gy/mice              | 20 mg/kg/day for 7 days before and then up to 30 days postradiation | Protects from radiation-induced injury, in part, via activation of Sirt1                            | [343]     |
|                                | Skin                            | 35 Gy/mice             | 1% by weight                              | Inhibits TGF-β signaling                                                                          | [338]     |
|                                | Lung                            | 13 Gy/mice             | 100 mg/kg/day for 7 days                  | Prevents lung injury by reducing inflammation and fibrosis                                         | [344]     |
| rhNRG-1β                       | Heart                           | 20 Gy/rats             | 15 µg/kg, 3 days before and 7 days after radiation | Prevents fibrosis and preserves cardiac function via the ErbB2-ERK-Sirt1 signaling pathway        | [345]     |
| Silibinin                      | Breast                          | 46.8-50.4 Gy/humans    | 400 IU for 6 months                       | Vitamin E may be clinically useful in preventing fibrosis after radiation in high-risk patients    | [346]     |
| SOD gliadin                    | Hind leg/skin                   | 25 Gy/mice             | 10000 units/kg/day for 8 days             | Reduces dermal thickness and fibrosis after irradiation                                            | [347]     |
| Soy isoavones                  | Prostate                        | 73.8 to 77.5 Gy/humans | 200 mg tablet containing 50 mg soy isoflavones (genistein, daidzein, and glycine at a ratio of 1.1 : 1 : 0.2) | Reduces the urinary, intestinal, and sexual adverse effects in patients with prostate cancer receiving radiation therapy | [348]     |
|                                | Lung                            | 12 Gy/mice             | 50 mg/kg/day, 3 days before and up to 4 months after radiation | Mitigates inflammatory infiltrates and radiation-induced lung injury                               | [349]     |
|                                | Lung                            | 10 Gy                  | 250 mg/kg/day, 3-day pretreatment         | Inhibits the infiltration and activation of macrophages and neutrophils induced by radiation in the lungs | [350]     |
|                                | Lung                            | 12 Gy/mice             | 250 mg/kg/day, 3-day pretreatment and up to 4 months after radiation | Inhibits the infiltration and activation of macrophages and neutrophils induced by radiation in the lungs | [349]     |
|                                | Lung                            | 14 Gy/mice             | 32 mg/kg/day                              | Inhibits TGF-β signaling; taurine essential amino acid is involved in osmoregulation, antioxidation, detoxification, membrane stabilization, neuromodulation, cardiac function, and central nervous system development | [351]     |
| Taurine                        | Brain                           | 6 Gy/rats              | 2 oral doses of 500 mg/kg/day for 2 weeks  | Taurine has antioxidant, anti-inflammatory, and antiapoptotic effects                              | [352]     |
|                                | Sperm cells                     | 8 Gy/mice spermatocytes (GC-2 cells) | 40 mM                                    | Activates Nrf2/HO-1 signaling                                                                     | [353]     |
| Vitamin E                      | Lung & heart                    | 20 Gy/rats             | 2.5% of diet 2 weeks before radiation or 150 mg injected 4 h before radiation | Protects lungs and heart tissues from radiation damage                                             | [354]     |
|                                | Lung                            | 14 Gy/rats             | 1.1 mg/day dissolved in 0.1 mL olive oil injected | Protects against the development of RIF                                                             | [355]     |
patients. ROS is one of the main drivers of epigenetic reprogramming of myofibroblasts, and targeting ROS could prevent many of the changes associated with fibrosis, as shown in Figure 2. To treat and prevent RIF, there are several strategies that can be used including inhibition of epigenetic modulators, inhibition of the TGF-β signaling pathway [284, 285], or inhibition of ROS, using antioxidants as shown in Table 1. Targeting the TGF-β signaling pathway or targeting the epigenetic modifications directly can prevent the epigenetic reprogramming of fibroblast cells and RIF. However, the main problem with these strategies is that there are side effects due to lack of specificity. Globally reducing epigenetic factors or TGF-β signaling can result in damage to other cells or organs not affected by RIF. However, increasing the antioxidant capacity of cells to physiologically relevant levels during and after radiation therapy is an ideal strategy to prevent RIF with minimal side effects. As discussed above, antioxidants also prevent the activation of the TGF-β signaling pathway and/or epigenetic modifications observed after radiation exposure. Therefore, removing or scavenging ROS by natural antioxidant compounds and/or mimics of antioxidant enzymes that are safe and well tolerated for clinical use may have significant potential to prevent RIF safely in patients.

Several different types of antioxidants and antifibrotic agents have demonstrated efficacy in preventing radiation damage and inhibiting acute molecular changes that drive the fibrotic phenotype in a variety of RIF animal models (see Table 1). Recent studies using small molecule antioxidants that mimic SOD activity, MnTE-2-PyP or MnTnBuOE-2-PyP, protect from acute and chronic fibrosis by preventing fibroblast activation and underlying reprogramming into activated myofibroblasts [286, 287]. For this reason, MnTnBuOE-2-PyP is currently in clinical trials as a radioprotector for several kinds of cancer [288–290]. In addition, another SOD mimic, GC4419, has also been shown to be an effective radioprotector and is in clinical trials for head and neck cancers. Given that these molecules do not protect tumors from radiation damage, these SOD mimics are a very promising therapy for the prevention of RIF. We predict that in the near future, these compounds will be available for patients to protect from RIF and potentially treat other fibrotic disorders by mitigating the epigenetic changes that drive fibrosis.

### Conflicts of Interest

There are no conflicts of interest for the authors except Dr. Rebecca E. Oberley-Deegan. Dr. Oberley-Deegan is a consultant with BioMimetic Pharmaceutical Inc. and holds equities in BioMimetic Pharmaceutical Inc.

### Authors’ Contributions

Shashank Shrishimal wrote the manuscript. Annie Kosmacek and Rebecca Oberley-Deegan worked with Shashank Shrishimal to formulate ideas for the manuscript and helped edit the manuscript.

### Acknowledgments

This study is supported by National Institutes of Health Grants 1R01CA178888 and NIH SP20 GM103480 COBRE and Fred & Pamela Buffett Cancer Center Support Grant P30CA036727.

### References

1. T. Wynn, “Cellular and molecular mechanisms of fibrosis,” *The Journal of Pathology*, vol. 214, no. 2, pp. 199–210, 2008.
2. L. Incrocci, “Radiotherapy for prostate cancer and sexual health,” *Translational Andrology and Urology*, vol. 4, no. 2, pp. 124–130, 2015.
3. J. P. Williams, C. J. Johnston, and J. N. Finkelstein, “Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?,” *Current Drug Targets*, vol. 11, no. 11, pp. 1386–1394, 2010.
4. M. S. Litwin, R. D. Hays, A. Fink et al., “Quality-of-life outcomes in men treated for localized prostate cancer,” *The Journal of the American Medical Association*, vol. 273, no. 2, pp. 129–135, 1995.
5. T. J. Whelan, M. Levine, J. Julian, P. Kirkbride, P. Skingley, and Ontario Clinical Oncology Group, “The effects of radiation therapy on quality of life of women with breast carcinoma,” *Cancer*, vol. 88, no. 10, pp. 2260–2266, 2000.
[6] P. R. Graves, F. Siddiqui, M. S. Anscher, and B. Movsas, “Radiation pulmonary toxicity: from mechanisms to management,” in *Seminars in Radiation Oncology*, vol. 20, no. 3, pp. 201–207, Elsevier, 2010.

[7] C. Xiao, A. H. Miller, J. Felger, D. M. Gordon, S. M. de Toledo, D. Pain, and E. I. Azzam, “Oxidative—reduction (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutic strategies,” *Clinical and Translational Oncology*, vol. 20, no. 8, pp. 975–988, 2018.

[8] C. Weigel, P. Schmezer, C. Plass, and O. Popanda, “Epigenetics in radiation-induced fibrosis,” *Oncogene*, vol. 34, no. 17, pp. 2145–2155, 2015.

[9] T. Yamamori, T. Sasagawa, O. Ichii et al., “Analysis of the mechanism of radiation-induced upregulation of mitochondrial abundance in mouse fibroblasts,” *Journal of Radiation Research*, vol. 58, no. 3, pp. 292–301, 2017.

[10] T. Shimura, M. Sasatani, H. Kawai et al., “A comparison of radiation-induced mitochondrial damage between neural progenitor stem cells and differentiated cells,” *Cell Cycle*, vol. 16, no. 6, pp. 565–573, 2017.

[11] B. N. Pandey, D. M. Gordon, S. M. de Toledo, D. Pain, and E. I. Azzam, “Normal human fibroblasts exposed to high- or low-dose ionizing radiation: differential effects on mitochondrial protein import and membrane potential,” *Antioxidants & Redox Signaling*, vol. 8, no. 7–8, pp. 1253–1261, 2006.

[12] J. K. Leach, G. van Tuyle, P. S. Lin, R. Schmidt-Ullrich, and R. B. Mikkelsen, “Ionizing radiation-induced, mitochondrial-dependent generation of reactive oxygen/nitrogen,” *Cancer Research*, vol. 61, no. 10, pp. 3894–3901, 2001.

[13] K. A. Mapuskar, K. H. Filippo, J. D. Schoenfeld et al., “Mitochondrial superoxide increases age-associated susceptibility of human dermal fibroblasts to radiation and chemotherapy,” *Cancer Research*, vol. 77, no. 18, pp. 5054–5067, 2017.
[36] K. McDaniel, F. Meng, N. Wu et al., “Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice,” *Hepatology*, vol. 65, no. 2, pp. 544–559, 2017.

[37] Y. Wu, F. Bu, H. Yu et al., “Methylation of Septin 9 mediated by DNMT3a enhances hepatic stellate cells activation and liver fibrogenesis,” *Toxicology and Applied Pharmacology*, vol. 315, pp. 35–49, 2017.

[38] R. Neary, C. J. Watson, and J. A. Baugh, “Epigenetics and the overhanging wound: the role of DNA methylation in fibrosis,” *Fibrogenesis & Tissue Repair*, vol. 8, no. 1, p. 18, 2015.

[39] A. Page, P. Paoli, E. Moran Salvador, S. White, J. French, and J. Mann, “Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape,” *Journal of Hepatology*, vol. 64, no. 3, pp. 661–673, 2016.

[40] W. A. Neveu, S. T. Mills, B. S. Staitieh, and V. Sueblin, “TGF-β1 epigenetically modifies Thyl-1 expression in primary lung fibroblasts,” *American Journal of Physiology-Cell Physiology*, vol. 309, no. 9, pp. C616–C626, 2015.

[41] S. Terrazzino, L. Deantonio, S. Cargnin et al., “DNA methyltransferase gene polymorphisms for prediction of radiation-induced skin fibrosis after treatment of breast cancer: a multifactorial genetic approach,” *Cancer Research and Treatment*, vol. 49, no. 2, pp. 464–472, 2017.

[42] Z. Qipa and Z. Hengshu, “The expression of DNMT1 in pathologic scar fibroblasts and the effect of 5-aza-2-deoxycytidine on cytokines of pathologic scar fibroblasts,” *Wounds: A Compendium of Clinical Research and Practice*, vol. 26, no. 5, pp. 139–146, 2014.

[43] I. Pogribny, I. Koturbash, V. Tryndyak et al., “Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus,” *Molecular Cancer Research*, vol. 3, no. 10, pp. 553–561, 2005.

[44] F. McDonnell, M. Irraten, A. F. Clark, C. J. O’Brien, and D. M. Wallace, “Hyposia-induced changes in DNA methylation alter RASAL1 and TGFβ1 expression in human trabecular meshwork cells,” *PLoS One*, vol. 11, no. 4, article e0153354, 2016.

[45] B. Tampe, U. Steinle, D. Tampe et al., “Low-dose hyalurazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression,” *Kidney International*, vol. 91, no. 1, pp. 157–176, 2017.

[46] X. Xu, X. Tan, M. S. Hulshoff, T. Wilhelmi, M. Zeisberg, and E. M. Zeisberg, “Hyposia-induced endothelial–mesenchymal transition is associated with RASAL1 promoter hypermethylation in human coronary endothelial cells,” *FEBS Letters*, vol. 590, no. 8, pp. 1222–1233, 2016.

[47] Y. Mao, “Hypermethylation of RASAL1: a key for renal fibrosis,” *eBioMedicine*, vol. 2, no. 1, pp. 7–8, 2015.

[48] K. H. Kim, H. M. Ryu, S. H. Oh et al., “Effect of DNA demethylation in experimental encapsulating peritoneal sclerosis,” *Therapeutic Apheresis and Dialysis*, vol. 18, no. 6, pp. 628–636, 2014.

[49] B. Tampe, D. Tampe, C. A. Muller et al., “Tet3-mediated hydroxylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis,” *Journal of the American Society of Nephrology*, vol. 25, no. 5, pp. 905–912, 2014.

[50] W. Bechtel, S. McGooohan, E. M. Zeisberg et al., “Methylation determines fibroblast activation and fibrogenesis in the kidney,” *Nature Medicine*, vol. 16, no. 5, pp. 544–550, 2010.

[51] F. Yu, Z. Lu, B. Chen, X. Wu, P. Dong, and J. Zheng, “Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated patched1 methylation,” *Journal of Cellular and Molecular Medicine*, vol. 19, no. 11, pp. 2617–2632, 2015.

[52] M. Zeybel, T. Hardy, Y. K. Wong et al., “Multigenerational epigenetic adaptation of the hepatic wound-healing response,” *Nature Medicine*, vol. 18, no. 9, pp. 1369–1377, 2012.

[53] Q. Xiao, D. Zhou, A. A. Rucki et al., “Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation,” *Cancer Research*, vol. 76, no. 18, pp. 5395–5404, 2016.

[54] T. Yoshida, H. Ogata, M. Kamio et al., “SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis,” *Journal of Experimental Medicine*, vol. 199, no. 12, pp. 1701–1707, 2004.

[55] C. Dees, I. Schlottmann, R. Funke et al., “The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis,” *Annals of the Rheumatic Diseases*, vol. 73, no. 6, pp. 1232–1239, 2014.

[56] C. Xu, J. Zhao, W. T. Y. Lo et al., “Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis,” *The International Journal of Biological Markers*, vol. 27, no. 4, pp. 314–321, 2012.

[57] G. Chappell, K. Kutanzi, T. Uehara et al., “Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice,” *International Journal of Cancer*, vol. 134, no. 12, pp. 2778–2788, 2014.

[58] A. M. Scruggs, H. B. Koh, P. Tripathi, N. J. Leeper, E. S. White, and S. K. Huang, “Loss of CDKN2B promotes fibrosis via increased fibroblast differentiation rather than proliferation,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 59, no. 2, pp. 200–214, 2018.

[59] Y. Wang, P. S. Fan, and B. Kahaleh, “Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts,” *Arthritis and Rheumatism*, vol. 54, no. 7, pp. 2271–2279, 2006.

[60] S. K. Huang, A. S. Fisher, A. M. Scruggs et al., “Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibroitic fibroblasts from humans and mice,” *The American Journal of Pathology*, vol. 177, no. 5, pp. 2245–2255, 2010.

[61] K. Takenaka, A. Gemma, A. Yoshimura et al., “Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis,” *Molecular Medicine Reports*, vol. 2, no. 1, pp. 73–80, 2009.

[62] M. Elkouris, H. Kontaki, A. Stavropoulos et al., “SET9-mediated regulation of TGF-β signaling links protein methylation to pulmonary fibrosis,” *Cell Reports*, vol. 15, no. 12, pp. 2733–2744, 2016.

[63] E.-B. Bian, C. Huang, H. Wang et al., “Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats,” *Toxicology Letters*, vol. 224, no. 2, pp. 175–185, 2014.

[64] Y. Zeng, Y. Cui, J. Ma et al., “Lung injury and expression of p53 and p16 in Wistar rats induced by respirable chrysotile fiber dust from four primary areas of China,” *Environment...*
X. Pan, Z. Chen, R. Huang, Y. Yao, and G. Ma, 2018.

M. Niemantsverdriet, E. de Jong, J. A. Langendijk, H. H. Kampinga, and R. P. Coppe, 2003.

C. B. Westbury, A. Freeman, M. Rashid, A. Pearson, J. R. Yarnold, and S. C. Short, 2014.

M. Roderfeld, T. Rath, S. Pasupuleti et al., 2012.

Y. Komatsu, T. Waku, N. Iwasaki, W. Ono, C. Yamaguchi et al., 2010.

J. Raiche, R. Rodriguez-Juarez, I. Pogribny, and O. Kovalchuk, 2012.

S. L. Archer, G. Marsboom, G. H. Kim et al., 2010.

J. Komatsu, T. Waku, N. Iwasaki, W. Ono, C. Yamaguchi et al., 2006.

J. A. Langendijk, H. H. Kampinga, and R. P. Coppe, 2003.

M. Niemantsverdriet, E. de Jong, J. A. Langendijk, H. H. Kampinga, and R. P. Coppe, 2003.

C. B. Westbury, A. Freeman, M. Rashid, A. Pearson, J. R. Yarnold, and S. C. Short, 2014.

M. Roderfeld, T. Rath, S. Pasupuleti et al., 2012.

J. Raiche, R. Rodriguez-Juarez, I. Pogribny, and O. Kovalchuk, 2012.

S. L. Archer, G. Marsboom, G. H. Kim et al., 2010.

M. Roderfeld, T. Rath, S. Pasupuleti et al., “Bone marrow transplantation improves hepatic fibrosis in Abcb 4−/− mice via Th1 response and matrix metalloproteinase activity,” Gut, vol. 61, no. 6, pp. 907–916, 2012.

Y. Komatsu, T. Waku, N. Iwasaki, W. Ono, C. Yamaguchi et al., 2006.

J. Raiche, R. Rodriguez-Juarez, I. Pogribny, and O. Kovalchuk, “Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice,” Biochemical and Biophysical Research Communications, vol. 325, no. 1, pp. 39–47, 2004.

Y.-T. Chang, C. C. Yang, S. Y. Pan et al., “DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys,” The Journal of Clinical Investigation, vol. 126, no. 2, pp. 721–731, 2016.

S. Zhao, M. Cao, H. Wu, Y. Hu, and X. Xue, “5-aza-2-deoxycytidine inhibits the proliferation of lung fibroblasts in neonatal rats exposed to hyperoxia,” Peditric & Neonatology, vol. 58, no. 2, pp. 122–127, 2017.

K. Kornicka, K. Marycz, M. Maredziak, K. A. Tomaszewski, and J. Nicponi, “The effects of the DNA methyltransferase inhibitor 5-azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells,” Journal of Cellular and Molecular Medicine, vol. 21, no. 2, pp. 387–401, 2017.

M. Hitchler, K. Wikainapakul, L. Yu, K. Powers, W. Attatipaholkun, and F. Domann, “Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells,” Epigenetics, vol. 1, no. 4, pp. 163–171, 2006.

A. C. E. Campos, F. Molognoni, F. H. M. Melo et al., “Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation,” Neoplasia, vol. 9, no. 12, pp. 1111–1121, 2007.

X. Pan, Z. Chen, R. Huang, Y. Yao, and G. Ma, “Transforming growth factor β1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts,” PLoS One, vol. 8, no. 4, article e60335, 2013.

H. Tao, J. J. Yang, K. H. Shi, and J. Li, “Epigenetic factors MeCP2 and HDAC6 control α-tubulin acetylation in cardiac fibroblast proliferation and fibrosis,” Inflammation Research, vol. 65, no. 5, pp. 415–426, 2016.

E.-B. Bian, C. Huang, H. Wang et al., “The role of methyl-CpG binding protein 2 in liver fibrosis,” Toxicology, vol. 309, pp. 9–14, 2013.

C. De Felice, F. D. Ragione, C. Signorini et al., “Oxidative brain damage in MeCP2 mutant murine models of Rett syndrome,” Neurobiology of Disease, vol. 68, pp. 66–77, 2014.

D. F. Bebensee, K. Can, and M. Müller, “Increased mitochondrial mass and cytosolic redox imbalance in hippocampal astrocytes of a mouse model of Rett syndrome: subcellular changes revealed by ratiometric imaging of JC-1 and roGFP1 fluorescence,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 3064016, 15 pages, 2017.

N. Shulyakova, A. C. Andrezza, L. R. Mills, and J. H. Eubanks, “Mitochondrial dysfunction in the pathogenesis of Rett syndrome: implications for mitochondria-targeted therapies,” Frontiers in Cellular Neuroscience, vol. 11, 2017.

A. Pecorelli, C. Cervellati, A. Cortelazzo et al., “Protemic analysis of 4-hydroxynonenal and nitrotyrosine modified proteins in RIT fibroblasts,” The International Journal of Biochemistry & Cell Biology, vol. 81, no. Part B, pp. 236–245, 2016.

H. Kimura and K. Shiotia, “Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt 1,” Journal of Biological Chemistry, vol. 278, no. 7, pp. 4806–4812, 2003.

H. Tao, J. J. Yang, W. Hu, K. H. Shi, Z. Y. Deng, and J. Li, “MeCP2 regulation of cardiac fibroblast proliferation and fibrosis by down-regulation of DUSP5,” International Journal of Biological Macromolecules, vol. 82, pp. 68–75, 2016.

I. Koturbash, N. M. Jadayi, K. Kutanzi et al., “Fractionated low-dose exposure to ionizing radiation leads to DNA damage, epigenetic dysregulation, and behavioral impairment,” Environmental Epigenetics, vol. 2, no. 4, 2016.

Y. Inytskyy, I. Koturbash, and O. Kovalchuk, “Radiation-induced bystander effects in vivo are epigenetically regulated in a tissue-specific manner,” Environmental and Molecular Mutagenesis, vol. 50, no. 2, pp. 105–113, 2009.

J. Mann, D. C. K. Chu, A. Maxwell et al., “MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis,” Gastroenterology, vol. 138, no. 2, pp. 705–714.e4, 2010.

H. Tao, C. Huang, J. J. Yang et al., “MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats,” Toxicology, vol. 290, no. 2–3, pp. 327–333, 2011.

I. Afanas’ev, “New nucleophilic mechanisms of ROS-dependent epigenetic modifications: comparison of aging and cancer,” Aging and Disease, vol. 5, no. 1, pp. 52–62, 2014.

I. Afanas’ev, “Mechanisms of superoxide signaling in epigenetic processes: relation to aging and cancer,” Aging and Disease, vol. 6, no. 3, pp. 216–227, 2015.

S.-H. Ryu, E. Y. Park, S. Kwak et al., “Protective effect of α-lipoic acid against radiation-induced fibrosis in mice,” Oncotarget, vol. 7, no. 13, pp. 15554–15565, 2016.

Z. Zeng, S. Cheng, H. Chen et al., “Activation and overexpression of Sirt 1 attenuates lung fibrosis via P 300,” Biochemical and Biophysical Research Communications, vol. 486, no. 4, pp. 1021–1026, 2017.

M. He, B. Zheng, Y. Zhang et al., “KLF4 mediates the link between TGF-β1-induced gene transcription and H3 acetylation in vascular smooth muscle cells,” The FASEB Journal, vol. 29, no. 9, pp. 4059–4070, 2015.

A. Bugayev-Twum, A. Advani, S. L. Advani et al., “High glucose induces Smad activation via the transcriptional...
coregulator p 300 and contributes to cardiac fibrosis and hypertrophy,” Cardiovascular Diabetology, vol. 13, no. 1, p. 89, 2014.

[95] Y. Tian, Y. Yang, L. Gao et al., “Expression of histone deacetylase-1 and p 300 in aristolochic acid nephropathy models,” Toxicology Mechanisms and Methods, vol. 24, no. 6, pp. 377–384, 2014.

[96] J. Zhang, Y. Li, K. Shan et al., “Sublytic C5b-9 induces IL-6 and TGF-β1 production by glomerular mesangial cells in rat Thy-1 nephritis through p 300-mediated C/EBPβ acetylation,” The FASEB Journal, vol. 28, no. 3, pp. 1511–1525, 2014.

[97] Y. Asano and M. Trojanowska, “Fli 1 represses transcription of the human α2 (I) collagen gene by recruitment of the HDAC1/p 300 complex,” PLoS One, vol. 8, no. 9, article e74930, 2013.

[98] C.-L. Chung, J. R. Sheu, W. L. Chen et al., “Histone deacetylase inhibitor m-carboxycinnamic acid biohydroxamide attenuates plasminogen activator inhibitor–1 expression in human pleural mesothelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, no. 4, pp. 437–445, 2012.

[99] T. Zhao, Y. Satou, K. Sugata et al., “HTLV-1 bZIP factor enhances TGF-β signaling through p 300 coactivator,” Blood, no. 7, pp. 1865–1876, 2011.

[100] J. Y. Lim, M. A. Oh, W. H. Kim, H. Y. Sohn, and S. I. Park, “AMP-activated protein kinase inhibits TGF-β-mediated fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p 300.” Journal of Cellular Physiology, vol. 227, no. 3, pp. 1081–1089, 2012.

[101] A. K. Ghosh, S. Bhattacharyya, R. Lafyatis et al., “p 300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis,” Journal of Investigative Dermatology, vol. 133, no. 6, pp. 1302–1310, 2013.

[102] C. D. Bondi, N. Manickam, D. Y. Lee et al., “NAD (P) H oxidase mediates TGF-β1–induced activation of kidney myofibroblasts,” Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 93–102, 2010.

[103] A. Chatterjee, E. A. Kosmacek, and R. E. Oberley-Deegan, “MnTE-2-PyP treatment, or NOX4 inhibition, protects against radiation-induced damage in mouse primary prostate fibroblasts by inhibiting the TGF-beta 1 signaling pathway,” Radiation Research, vol. 187, no. 3, pp. 367–381, 2017.

[104] L. Hu, Y. Yu, H. Huang et al., “Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis,” Frontiers in Immunology, vol. 7, 2017.

[105] Y. Yang, K. Liu, Y. Liang, Y. Chen, Y. Chen, and Y. Gong, “Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad 3 signaling pathway in vitro,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 3, pp. 2746–2754, 2015.

[106] Y. Sunagawa, Y. Katansaka, K. Hasegawa, and T. Morimoto, “Clinical applications of curcumin,” PharmaNutrition, vol. 3, no. 4, pp. 131–135, 2015.

[107] Y.-J. Tsai, T. Tsai, P. C. Peng, P. T. Li, and C. T. Chen, “Histone acetyltransferase p 300 is induced by p38MAPK after photodynamic therapy: the therapeutic response is increased by the p300HAT inhibitor anacardic acid,” Free Radical Biology and Medicine, vol. 86, pp. 118–132, 2015.

[108] Q. Tong, Y. Zhu, J. W. Galaske et al., “MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell,” Free Radical Biology and Medicine, vol. 101, pp. 32–43, 2016.

[109] M. Putker, H. R. Vos, and T. B. Dansen, “Intermolecular disulfide-dependent redox signalling,” in Biochemical Society Transactions, vol. 42, no. 4pp. 971–978, Portland Press Limited, 2014.

[110] M. D. Vasudevarao, P. Mizar, S. Kumari et al., “Naphthoquinone-mediated inhibition of lysine acetyltransferase KAT3B/p 300, basis for non-toxic inhibitor synthesis,” Journal of Biological Chemistry, vol. 289, no. 11, pp. 7702–7717, 2014.

[111] Y. Wang, J. Yang, K. Yang et al., “The biphasic redox sensing of SENP3 accounts for the HIF-1 transcriptional activity shift by oxidative stress,” Acta Pharmacologica Sinica, vol. 33, no. 7, pp. 953–963, 2012.

[112] H. Liu, M. Jie, Z. He, H. F. Li, and J. M. Lin, “Study of antioxidant effects on malignant glioma cells by constructing a tumor-microvascular structure on microchip,” Analytica Chimica Acta, vol. 978, pp. 1–9, 2017.

[113] F. Moura, K. de Andrade, J. Farias dos Santos, and M. Fonseca Goulart, “Lipoic acid: its antioxidant and anti-inflammatory role and clinical applications,” Current Topics in Medicinal Chemistry, vol. 15, no. 5, pp. 458–483, 2015.

[114] A.-L. A. L. S. Oluşan and P. Fibrozisi, “Alpha-lipoic acid inhibits peridural fibrosis following laminectomy through the inactivation of TGF-β1, PDGF, PAI-1 and IL-6 expressions,” Turkish Neurosurgery, vol. 25, no. 1, pp. 90–99, 2015.

[115] J. H. Jung, J. Jung, S. K. Kim et al., “Alpha lipoic acid attenuates radiation-induced thyroid injury in rats,” PloS One, vol. 9, no. 11, article e112253, 2014.

[116] H. Liu, A. Liu, C. Shi, and B. Li, “Curcumin suppresses transforming growth factor-β1-induced cardiac fibroblast differentiation via inhibition of Smad-2 and p 38 MAPK signaling pathways,” Experimental and Therapeutic Medicine, vol. 11, no. 3, pp. 998–1004, 2016.

[117] D. K. Deb, Y. Chen, J. Sun, Y. Wang, and Y. C. Li, “ATP-citrate lyase is essential for high glucose-induced histone hyperacetylation and fibrogenic gene upregulation in mesangial cells,” American Journal of Physiology-Renal Physiology, vol. 313, no. 2, pp. F423–F429, 2017.

[118] T. Mao, L. Gao, H. Li, and J. Li, “Pigment epithelium-derived factor inhibits high glucose induced oxidative stress and fibrosis of cultured human glomerular mesangial cells,” Saudi Medical Journal, vol. 32, no. 8, pp. 769–777, 2011.

[119] L. Du, M. Hao, C. Li et al., “Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose cultured lens, and SRA01/04 cells through transforming growth factor-β2/phosphoinositide 3-kinase/Akt pathway,” Molecular and Cellular Endocrinology, vol. 452, pp. 44–56, 2017.

[120] A. A. Cluntun, H. Huang, L. Dai, X. Liu, Y. Zhao, and J. W. Locasale, “The rate of glycolysis quantitatively mediates specific histone acetylation sites,” Cancer & Metabolism, vol. 8, no. 1, p. 10, 2015.

[121] S. Kotla and G. N. Rao, “Reactive oxygen species (ROS) mediate p300-dependent STAT1 protein interaction with...
peroxisome proliferator-activated receptor (PPAR)-γ in CD36 protein expression and foam cell formation,” Journal of Biological Chemistry, vol. 290, no. 51, pp. 30306–30320, 2015.

[122] S. Kotla, N. K. Singh, and G. N. Rao, “ROS via BTK-p300-STAT1-PPARγ signaling activation mediates cholesterol crystals-induced CD36 expression and foam cell formation,” Redox Biology, vol. 11, pp. 350–364, 2017.

[123] S.-S. Rao, X. Y. Zhang, M. J. Shi et al., “Suberoylanilide hydroxamic acid attenuates paraquat-induced pulmonary fibrosis by preventing Smad 7 from deacetylation in rats,” Journal of Thoracic Disease, vol. 8, no. 9, pp. 2485–2494, 2016.

[124] W. Lei, K. Zhang, X. Pan et al., “Histone deacetylase 1 is required for transforming growth factor-β1-induced epithelial–mesenchymal transition,” The International Journal of Biochemistry & Cell Biology, vol. 42, no. 9, pp. 1489–1497, 2010.

[125] T. Marumo, K. Hishikawa, M. Yoshikawa, J. Hirahashi, S. Kawachi, and T. Fujita, “Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury,” American Journal of Physiology-Renal Physiology, vol. 298, no. 1, pp. F133–F141, 2010.

[126] Y. Liu, Z. Wang, J. Wang et al., “A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling,” Liver International, vol. 33, no. 4, pp. 504–515, 2013.

[127] C. Cianciolo Cosentino, N. I. Skrypnyk, L. L. Brilli et al., “Histone deacetylase inhibitor enhances recovery after AKI,” Journal of the American Society of Nephrology, vol. 24, no. 6, pp. 993–953, 2013.

[128] H. F. Nural-Guvener, L. Zakharaov, J. Nimlos, S. Popovic, D. Mastroeni, and M. A. Gaballa, “HDAC class I inhibitor, mepogenostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation,” Fibrogenesis & Tissue Repair, vol. 7, no. 1, p. 10, 2014.

[129] K. Palumbo-Zerr, P. Zerr, A. Distler et al., “Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis,” Nature Medicine, vol. 21, no. 2, pp. 150–158, 2015.

[130] H. Nural-Guvener, L. Zakharaov, L. Feehery, S. Slujkic, and M. Gaballa, “Anti-fibrotic effects of class I HDAC inhibitor, mepogenostat is associated with IL-6/Stat3 signaling in ischemic heart failure,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 11482–11499, 2015.

[131] K. B. Schuetze, M. S. Strutton, W. W. Blakeslee et al., “Overlapping and divergent actions of structurally distinct histone deacetylase inhibitors in cardiac fibroblasts,” Journal of Pharmacology and Experimental Therapeutics, vol. 361, no. 1, pp. 140–150, 2017.

[132] X. Han, C. Hao, L. Li et al., “HDAC4 stimulates MRTF-A expression and drives fibrogenesis in hepatic stellate cells by targeting miR-206,” Oncotarget, vol. 8, no. 29, pp. 47586–47594, 2017.

[133] M. Pang and S. Zhuang, “Histone deacetylase: a potential therapeutic target for fibrotic disorders,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 2, pp. 266–272, 2010.

[134] T. Kato, Y. Shimono, M. Hasegawa et al., “Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress,” Cancer Research, vol. 69, no. 8, pp. 3597–3604, 2009.

[135] J.-Y. Chuang, W.-C. Chang, and J.-J. Hung, “Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells,” Free Radical Biology and Medicine, vol. 51, no. 12, pp. 2309–2318, 2011.

[136] M. Korfei, S. Skwarna, I. Hennenke et al., “Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis,” Thorax, vol. 70, no. 11, pp. 1022–1032, 2015.

[137] M. Schoepp, A. Ströse, and J. Haier, “Dysregulation of miRNA expression in cancer associated fibroblasts (CAF) and its consequences on the tumor microenvironment,” Cancers, vol. 9, no. 12, p. 54, 2017.

[138] L. Qin and Y.-P. Han, “Epigenetic repression of matrix metalloproteases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis,” The American Journal of Pathology, vol. 177, no. 4, pp. 1915–1928, 2010.

[139] W. Glenisson, V. Castronovo, and D. Waltregny, “Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1773, no. 10, pp. 1572–1582, 2007.

[140] K. Doyle and F. A. Fitzpatrick, “Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function,” Journal of Biological Chemistry, vol. 285, no. 23, pp. 17417–17424, 2010.

[141] T. Ago, T. Liu, P. Zhai et al., “A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy,” Cell, vol. 133, no. 6, pp. 978–993, 2008.

[142] X. Li, X. Q. Wu, T. Xu et al., “Role of histone deacetylases (HDACs) in progression and reversal of liver fibrosis,” Toxicology and Applied Pharmacology, vol. 306, pp. 58–68, 2016.

[143] M. R. Rountree, K. E. Bachman, and S. B. Baylin, “DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci,” Nature Genetics, vol. 25, no. 3, pp. 269–277, 2000.

[144] K. Ito, T. Hanazawa, K. Tomita, P. J. Barnes, and I. M. Adcock, “Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration,” Biochemical and Biophysical Research Communications, vol. 315, no. 1, pp. 240–245, 2004.

[145] S.-R. Yang, A. S. Chida, M. R. Bauter et al., “Cigarette smoke induces proinflammatory cytokine release by activation of NF-kB and posttranslational modifications of histone deacetylase in macrophages,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 291, no. 1, pp. L46–L57, 2006.

[146] K. K. Meja, S. Rajendrasozhan, D. Adenuga et al., “Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 3, pp. 312–323, 2008.

[147] T. R. Bartling, S. Subbaram, R. R. Clark, A. Chandrasekaran, S. Kar, and J. Andres Melendez, “Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression,” Free Radical Biology and Medicine, vol. 74, pp. 99–107, 2014.

[148] S. Rajendrasozhan, H. Yao, and I. Rahman, “Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD,” COPD: Journal of Chronic
Obstructive Pulmonary Disease, vol. 6, no. 4, pp. 291–297, 2009.

[149] K. Ito, M. Ito, W. M. Elliott et al., “Decreased histone deacetylase activity in chronic obstructive pulmonary disease,” New England Journal of Medicine, vol. 352, no. 19, pp. 1967–1976, 2005.

[150] K. Ito, S. Lim, G. Caramori, K. F. Chung, P. J. Barnes, and I. M. Adcock, “Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages,” The FASEB Journal, vol. 15, no. 6, pp. 1110–1112, 2001.

[151] P. J. Barnes, “Role of HDAC2 in the pathophysiology of COPD,” Annual Review of Physiology, vol. 71, no. 1, pp. 451–464, 2009.

[152] L. Jin, M. Q. Lin, Z. H. Piao et al., “Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2,” Journal of Hypertension, vol. 35, no. 7, pp. 1502–1512, 2017.

[153] A. Mengel, A. Ageeva, E. Georgi et al., “Nitric oxide modulates histone acetylation at stress genes by inhibition of histone deacetylases,” Plant Physiology, vol. 173, no. 2, pp. 1434–1452, 2017.

[154] S.-I. Oka, T. Ago, T. Kitazono, D. Zablocki, and J. Sadoshima, “The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy,” Journal of Molecular Medicine, vol. 87, no. 8, pp. 785–791, 2009.

[155] F. Conforti, E. R. Davies, C. J. Calderwood et al., “The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis,” Oncotarget, vol. 8, no. 30, pp. 48737–48754, 2017.

[156] W. Lin, Q. Zhang, L. Liu, S. Yin, Z. Liu, and W. Cao, “Klotho restoration via acetylation of peroxisome proliferation–activated receptor γ reduces the progression of chronic kidney disease,” Kidney International, vol. 92, no. 3, pp. 669–679, 2017.

[157] S. Svegliati, G. Marrone, A. Pezone et al., “Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis,” Science Signaling, vol. 7, no. 341, p. ra84, 2014.

[158] K. Jo, T. Nishino, Y. Obata, M. Kitamura, T. Koji, and S. Kohno, “Sasa suppresses peritoneal fibrosis in mice,” Peritoneal Dialysis International, vol. 35, no. 3, pp. 246–258, 2015.

[159] S. Noguchi, M. Eitoku, S. Moriya et al., “Regulation of gene expression by sodium valproate in epithelial-to-mesenchymal transition,” Lung, vol. 193, no. 5, pp. 691–700, 2015.

[160] G. Floris, M. Debiec-Rychter, R. Sciot et al., “High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model,” Clinical Cancer Research, vol. 15, no. 12, pp. 4066–4076, 2009.

[161] J. Mascarenhas, “Rationale for combination therapy in myelofibrosis,” Best Practice & Research Clinical Haematology, vol. 27, no. 2, pp. 197–208, 2014.

[162] M. Cetinkaya, M. Cansev, F. Cekmez et al., “Protective effects of valproic acid, a histone deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model,” PLoS One, vol. 10, no. 5, article e0126028, 2015.

[163] S.-H. Kang, Y. M. Seok, M. J. Song, H. A. Lee, T. Kurz, and I. Kim, “Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats,” Molecular Pharmacology, vol. 87, no. 5, pp. 782–791, 2015.

[164] C. Dausukho, Y. Chen, T. Noel et al., “Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury,” Free Radical Biology and Medicine, vol. 42, no. 12, pp. 1818–1825, 2007.

[165] G. Yang, X. Peng, Y. Hu et al., “4-Phenylbutyrate benefits traumatic hemorrhagic shock in rats by attenuating oxidative stress, not by attenuating endoplasmic reticulum stress,” Critical Care Medicine, vol. 44, no. 7, pp. e477–e491, 2016.

[166] A. Jangra, C. S. Srim, and M. Lahkar, “Lipopolysaccharide-induced behavioral alterations are alleviated by sodium phenylbutyrate via attenuation of oxidative stress and neuroinflammatory cascade,” Inflammation, vol. 39, no. 4, pp. 1441–1452, 2016.

[167] W. Zhou, K. Bercury, J. Cummiskey, N. Luong, J. Lebin, and C. R. Freed, “Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease,” Journal of Biological Chemistry, vol. 286, no. 17, pp. 14941–14951, 2011.

[168] Y. L. Chung, A.-J. Wang, and L.-F. Yao, “Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy,” Molecular Cancer Therapeutics, vol. 3, no. 3, pp. 317–325, 2004.

[169] S. Balaiya, K. K. Abu-Amero, A. A. Kondkar, and K. V. Chalam, “Sirtuins expression and their role in retinal diseases,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 3187594, 11 pages, 2017.

[170] R. H. Houtkoper, E. Pirinen, and J. Auwerx, “Sirtuins as regulators of metabolism and healthspan,” Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 225–238, 2012.

[171] S.-Y. Yang, S. L. Lin, Y. M. Chen, V. C. Wu, W. S. Yang, and K. D. Wu, “Downregulation of angiotensin type 1 receptor and nuclear factor-kB by sirtuin 1 contributes to renoprotection in unilateral ureteral obstruction,” Scientific Reports, vol. 6, no. 1, 2016.

[172] J. Zhang, Q. Z. Wang, S. H. Zhao et al., “Astaxanthin attenuated pressure overload-induced cardiac dysfunction and myocardial fibrosis: partially by activating SIRT1,” Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1861, no. 7, pp. 1715–1728, 2017.

[173] D. Cappetta, G. Esposito, E. Piegari et al., “SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of antracycline cardiomyopathy,” International Journal of Cardiology, vol. 205, pp. 99–110, 2016.

[174] Y.-g. Du, L.-p. Wang, J.-w. Qian, K.-n. Zhang, and K.-f. Chai, “Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats,” Chinese Journal of Integrative Medicine, vol. 22, no. 12, pp. 910–917, 2016.

[175] Y. Wu, X. Liu, Q. Zhou et al., “Silent information regulator 1 (SIRT1) ameliorates liver fibrosis via promoting activated stellate cell apoptosis and reversion,” Toxicology and Applied Pharmacology, vol. 289, no. 2, pp. 163–176, 2015.

[176] K. Huang, C. Chen, J. Hao et al., “Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular mesangial cells,” Molecular and Cellular Endocrinology, vol. 399, pp. 178–189, 2015.
[177] P. Zerr, K. Palumbo-Zerr, J. Huang et al., “Sirt 1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis,” *Annals of the Rheumatic Diseases*, vol. 75, no. 1, pp. 226–233, 2015.

[178] K. Huang, J. Huang, X. Xie et al., “Sirt 1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells,” *Free Radical Biology and Medicine*, vol. 65, pp. 528–540, 2013.

[179] L. Rong, J. Wu, W. Wang, R. P. Zhao, X. W. Xu, and D. Hu, “Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT),” *European Review for Medical and Pharmacological Sciences*, vol. 20, no. 10, pp. 2144–2150, 2016.

[180] S. M. Rizk, S. A. El-Maraghy, and N. N. Nassar, “A novel role for SIRT-1 in L-arginine protection against STZ induced myocardial fibrosis in rats,” *PloS One*, vol. 9, no. 12, article e114560, 2014.

[181] R. Mortuza, B. Feng, and S. Chakrabarti, “SIRT1 reduction causes renal and retinal injury in diabetes through endothelin 1 and transforming growth factor β1,” *Journal of Cellular and Molecular Medicine*, vol. 19, no. 8, pp. 1857–1867, 2015.

[182] B. Xiang, L. Han, X. Wang et al., “Nicotinamide phosphoribosyltransferase upregulation by phenylephrine reduces radiation injury in submandibular gland,” *International Journal of Radiation Oncology Biology Physics*, vol. 96, no. 3, pp. 538–546, 2016.

[183] L. Song, L. Ma, F. Cong et al., “Radioprotective effects of genistein on HL-7702 cells via the inhibition of apoptosis and DNA damage,” *Cancer Letters*, vol. 366, no. 1, pp. 100–111, 2015.

[184] G.-S. Oh, S. B. Lee, A. Karna et al., “Increased cellular NAD+ level through NQO1 enzymatic action has protective effects on bleomycin-induced lung fibrosis in mice,” *Tuberculosis and Respiratory Diseases*, vol. 79, no. 4, pp. 257–266, 2016.

[185] N. Braidy, G. J. Guillemín, H. Mansour, T. Chan-Ling, A. Poljak, and R. Grant, “Age-related changes in NAD+ metabolism oxidative stress and Sirt 1 activity in wistar rats,” *PloS One*, vol. 6, no. 4, article e19194, 2011.

[186] H. M. O’Hagan, W. Wang, S. Sen et al., “Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands,” *Cancer Cell*, vol. 20, no. 5, pp. 606–619, 2011.

[187] L. Santos, C. Escande, and A. Denicola, “Potential modulation of sirtuins by oxidative stress,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 9831825, 12 pages, 2016.

[188] M. Tanno, J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio, “Nucleo-cytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1,” *Journal of Biological Chemistry*, vol. 282, no. 9, pp. 6823–6832, 2007.

[189] J.-W. Hwang, H. Yao, S. Caito, I. K. Sundar, and I. Rahman, “Redox regulation of SIRT1 in inflammation and cellular senescence,” *Free Radical Biology and Medicine*, vol. 61, pp. 95–110, 2013.

[190] T. Takata, Y. Motoo, and N. Tomosugi, “Effect of Saikosokeishito, a Kampo medicine, on hydrogen peroxide-induced premature senescence of normal human dermal fibroblasts,” *Journal of Integrative Medicine*, vol. 12, no. 6, pp. 495–503, 2014.

[191] R. S. Said, E. el-Demerash, A. S. Nada, and M. M. Kamal, “Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly (ADP-ribose) polymerase 1 (PARP-1),” *Biochemical Pharmacology*, vol. 103, pp. 140–150, 2016.

[192] Z. Meng, J. Li, H. Zhao et al., “Resveratrol relieves ischemia-induced oxidative stress in the hippocampus by activating SIRT1,” *Experimental and Therapeutic Medicine*, vol. 10, no. 2, pp. 525–530, 2015.

[193] Y. Lou, Z. Wang, Y. Xu et al., “Resveratrol prevents doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of endoplasmic reticulum stress and the activation of the Sirt 1 pathway,” *International Journal of Molecular Medicine*, vol. 36, no. 3, pp. 873–880, 2015.

[194] P. Li, M. L. Liang, Y. Zhu et al., “Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts,” *World Journal of Gastroenterology: WJG*, vol. 20, no. 16, pp. 4646–4661, 2014.

[195] Y. S. Hori, A. Kuno, R. Hosoda et al., “Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 338, no. 3, pp. 784–794, 2011.

[196] J. Li, X. Qu, S. D. Ricardo, J. F. Bertram, and D. J. Nikolic-Paterson, “Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad 3,” *The American Journal of Pathology*, vol. 177, no. 3, pp. 1065–1071, 2010.

[197] S. Chung, H. Yao, S. Caito, J. W. Hwang, G. Arunachalam, and I. Rahman, “Regulation of SIRT1 in cellular functions: role of polyphenols,” *Archives of Biochemistry and Biophysics*, vol. 501, no. 1, pp. 79–90, 2010.

[198] X. Ji, J. Xiao, X. Sheng, X. Zhang, and M. Guo, “Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro,” *Drug Design, Development and Therapy*, vol. 10, pp. 1267–1277, 2016.

[199] F. Marampon, G. L. Gravina, C. Festuccia et al., “Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/Sirt1 axis,” *Journal of Endocrinological Investigation*, vol. 39, no. 4, pp. 411–422, 2016.

[200] M. R. Haussler, G. K. Whitfield, C. A. Haussler et al., “Chaperone eight-1, 25-dihydroxyvitamin D and Klotho: a tale of two renal hormones coming of age,” *Vitamins & Hormones*, vol. 100, pp. 165–230, 2016.

[201] L.-S. Qi, L. Yao, W. Liu et al., “Sirtuin type 1 mediates the retinal protective effect of hydrogen-rich saline against light-induced damage in rats,” *Investigative Ophthalmology & Visual Science*, vol. 56, no. 13, p. 8268, 2015.

[202] J. Duan, Y. Yin, G. Wei et al., “Chikusetsu saponin IVa confers cardioprotection via SIRT1/ERK1/2 and Homer1a pathway,” *Scientific Reports*, vol. 5, no. 1, 2015.

[203] K. W. Chung, Y. J. Choi, M. H. Park et al., “Molecular insights into SIRT1 protection against UVB-induced skin fibroblast senescence by suppression of oxidative stress and p 53 acetylation,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 70, no. 8, pp. 959–968, 2014.

[204] Y. Xie, W. Tu, J. Zhang et al., “SirT1 knockdown potentiates radiation-induced bystander effect through promoting c-Myc activity and thus facilitating ROS accumulation,” *Mutation
Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 772, pp. 23–29, 2015.

[205] A. Salminen, K. Kaarniranta, and A. Kauppinen, “Crosstalk between oxidative stress and SIRT1: impact on the aging process,” International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3834–3859, 2013.

[206] R. S. Khan, K. Dine, J. Das Sarma, and K. S. Shindler, “SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease,” Acta Neuropathologica Communications, vol. 2, no. 1, p. 3, 2014.

[207] K. Hasegawa, S. Wakino, K. Yoshioka et al., “Kidney-specific overexpression of Sirt 1 protects against acute kidney injury by retaining peroxisome function,” Journal of Biological Chemistry, vol. 285, no. 17, pp. 13045–13056, 2010.

[208] K. Huang, X. Gao, and W. Wei, “The crosstalk between sirt 1 and keap 1/Nrf 2/are anti-oxidative pathway forms a positive feedback loop to inhibit FN and TGF-β1 expressions in rat glomerular mesangial cells,” Experimental Cell Research, vol. 361, no. 1, pp. 63–72, 2017.

[209] D. M. Abd El Motteleb, I. A. A. E.-H. Ibrahim, and S. M. Elshazly, “Sildenafil protects against bile duct ligation induced hepatic fibrosis in rats: potential role for silent information regulator 1 (SIRT1),” Toxicology and Applied Pharmacology, vol. 335, pp. 64–71, 2017.

[210] K. Hasegawa, S. Wakino, K. Yoshioka et al., “Sirt 1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 51–56, 2008.

[211] M. Fernández-Galilea, P. Pérez-Matute, P. L. Prieto-Hontoria et al., “α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1851, no. 3, pp. 273–281, 2015.

[212] P. T. Pfuger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschop, “Sirt 1 protects against high-fat diet-induced metabolic damage,” Proceedings of the National Academy of Sciences, vol. 105, no. 28, pp. 9793–9798, 2008.

[213] K. Cao, X. Lei, H. Liu et al., “Polydatin alleviated radiation-induced lung injury through activation of Sirt 3 and inhibition of epithelial–mesenchymal transition,” Journal of Cellular and Molecular Medicine, vol. 21, no. 12, pp. 3264–3276, 2017.

[214] R. P. Jablonski, S. J. Kim, P. Cheres et al., “SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis,” The FASEB Journal, vol. 31, no. 6, pp. 2520–2532, 2017.

[215] M. L. Sosulski, R. Gongora, C. Feghali-Bostwick, J. A. Lasky, and C. G. Sanchez, “Sirtuin 3 deregulation promotes pulmonary fibrosis,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 72, no. 5, pp. glw151–glw602, 2016.

[216] H. Wang, S. Liu, S. Liu et al., “Enhanced expression and phosphorylation of Sirt 7 activates smad 2 and ERK signaling and promotes the cardiac fibrosis differentiation upon angiotensin-II stimulation,” PloS One, vol. 12, no. 6, article e0178530, 2017.

[217] S. Bindu, V. B. Pillai, A. Kanwal et al., “SIRT3 blocks myofibroblast differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 312, no. 1, pp. L68–L78, 2017.

[218] S.-O. Ka, I. H. Bang, E. J. Bae, and B. H. Park, “Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach 1, an Nrf 2 repressor,” The FASEB Journal, vol. 31, no. 9, pp. 3999–4010, 2017.

[219] W. Huang, H. Liu, S. Zhu et al., “Sirt 6 deficiency results in progression of glomerular injury in the kidney,” Aging, vol. 9, no. 3, pp. 1069–1083, 2017.

[220] S. Minagawa, J. Araya, T. Numata et al., “Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 3, pp. L391–L401, 2011.

[221] K. Tian, Z. Liu, J. Wang, S. Xu, T. You, and P. Liu, “Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factorκB signaling,” Translational Research, vol. 165, no. 3, pp. 374–386, 2015.

[222] A. E. Wyman, Z. Noor, R. Fishelevich et al., “Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 312, no. 6, pp. L945–L958, 2017.

[223] S. Araki, Y. Izumiya, T. Rotkunanda et al., “Sirt7 contributes to myocardial tissue repair by maintaining transforming growth factor-β signaling pathway,” Circulation, vol. 132, no. 12, pp. 1081–1093, 2015.

[224] M. Arteaga, N. Shang, X. Ding et al., “Inhibition of SIRT2 suppresses hepatic fibrosis,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 310, no. 11, pp. G1155–G1168, 2016.

[225] M. Ponnusamy, X. Zhou, Y. Yan et al., “Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy,” Journal of Pharmacology and Experimental Therapeutics, vol. 350, no. 2, pp. 243–256, 2014.

[226] P. Nguyen, S. Lee, D. Lorang-Leins, J. Trepel, and D. K. Smart, “SIRT2 interacts with β-catenin to inhibit Wnt signaling output in response to radiation-induced stress,” Molecular Cancer Research, vol. 12, no. 9, pp. 1244–1253, 2014.

[227] S. Shuld, U. T. Shankavaram, P. Nguyen, B. A. Stanley, and D. D. K. Smart, “Radiation-induced alteration of the brain proteome: understanding the role of the sirtuin 2 deacetylase in a murine model,” Journal of Proteome Research, vol. 14, no. 10, pp. 4104–4117, 2015.

[228] B. Wang, Y. Zhang, W. Cao, X. Wei, J. Chen, and W. Ying, “SIRT2 plays significant roles in lipopolysaccharides-induced neuroinflammation and brain injury in mice,” Neurochemical Research, vol. 41, no. 9, pp. 2490–2500, 2016.

[229] Y.-X. Luo, X. Tang, X. Z. An et al., “Sirt 4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity,” European Heart Journal, vol. 38, no. 18, pp. 1389–1398, 2017.

[230] G. Sun, M. A. Reddy, H. Yuan, L. Lanting, M. Kato, and R. Natarajan, “Epigenetic histone methylation modulates fibrotic gene expression,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2069–2080, 2010.

[231] Q. Guo, X. Li, H. Han et al., “Histone lysine methylation in TGF-β1 mediated p 21 gene expression in rat mesangial cells,” BioMed Research International, vol. 2016, Article ID 6927234, 9 pages, 2016.
[232] T. Irifuku, S. Doi, K. Sasaki et al., "Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression," Kidney International, vol. 89, no. 1, pp. 147–157, 2016.

[233] C. K. Abrass, K. Hansen, V. Popov, and O. Denisenko, "Alterations in chromatin are associated with increases in collagen III expression in aging nephropathy," American Journal of Physiology-Renal Physiology, vol. 300, no. 2, pp. F531–F539, 2011.

[234] S. Doi and T. Masaki, "Klotho as a therapeutic target during the development of renal fibrosis," in Scientific Aspects of Dialysis Therapy, pp. 178–183, Karger Publishers, 2017.

[235] Y. Yang, X. X. Chen, W. X. Li et al., "TZB2-mediated repression of Dkk 1 promotes hepatic stellate cell activation and hepatic fibrosis," Journal of Cellular and Molecular Medicine, vol. 21, no. 10, pp. 2317–2328, 2017.

[236] J. S. Davids, A. M. Carothers, B. C. Damas, and M. M. Bertagnolli, "Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis," Cancer Prevention Research, vol. 3, no. 3, pp. 348–358, 2010.

[237] O. Motiño, N. Agra, R. Brea Contras et al., "Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice," Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1862, no. 9, pp. 1710–1723, 2016.

[238] D. Gvaramia, M. E. Blauboer, R. Hanemaaijer, and V. Everts, "Role of caveolin-1 in fibrotic diseases," Matrix Biology, vol. 32, no. 6, pp. 307–315, 2013.

[239] Y. Y. Sanders, H. Liu, A. M. Scruuggs, S. R. Duncan, S. K. Huang, and V. J. Thannickal, "Epigenetic regulation of caveolin-1 gene expression in lung fibroblasts," American Journal of Respiratory Cell and Molecular Biology, vol. 56, no. 1, pp. 50–61, 2017.

[240] W. R. Coward, C. A. Feghali-Bostwick, G. Jenkins, A. J. Knox, and L. Pang, "A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis," The FASEB Journal, vol. 28, no. 7, pp. 3183–3196, 2014.

[241] L. Li, P. Qiu, B. Chen et al., "Reactive oxygen species contribute to arsenic-induced EZH2 phosphorylation in human bronchial epithelial cells and lung cancer cells," Toxicology and Applied Pharmacology, vol. 276, no. 3, pp. 165–170, 2014.

[242] X. Xiao, L. K. Senavirathna, X. Gou, C. Huang, Y. Liang, and L. Liu, "EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis," Physiological Reports, vol. 4, no. 17, article e12915, 2016.

[243] X. Zhou, X. Zang, M. Ponnusamy et al., "Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad 7 and phosphatase and tensin homolog expression," Journal of the American Society of Nephrology, vol. 27, no. 7, pp. 2092–2108, 2016.

[244] H. Shima, K. Sasaki, T. Suzuki et al., "A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways," Scientific Reports, vol. 7, no. 1, p. 1884, 2017.

[245] M. J. Perugorria, C. L. Wilson, M. Zeybel et al., "Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation," Hepatology, vol. 56, no. 3, pp. 1129–1139, 2012.

[246] Y. Niu, T. L. DesMarais, Z. Tong, Y. Yao, and M. Costa, "Oxidative stress alters global histone modification and DNA methylation," Free Radical Biology and Medicine, vol. 82, pp. 22–28, 2015.

[247] C. Polytarchou, R. Pfau, M. Hatzipostolou, and P. N. Tischlis, "The JmjC domain histone demethylase Ndy1 regulates redox homeostasis and protects cells from oxidative stress," Molecular and Cellular Biology, vol. 28, no. 24, pp. 7451–7464, 2008.

[248] M. L. Duquette, J. Kim, L. Z. Shi, and M. W. Berns, "LSD1 mediated changes in the local redox environment during the DNA damage response," PloS One, vol. 13, no. 8, article e0201907, 2018.

[249] S. Ramadoss, X. Chen, and C.-Y. Wang, "Histone demethylase KDM6B promotes epithelial-mesenchymal transition," Journal of Biological Chemistry, vol. 287, no. 53, pp. 44508–44517, 2012.

[250] N. L. Simone, B. P. Soule, D. Ly et al., "Ionizing radiation-induced oxidative stress alters miRNA expression," PloS One, vol. 4, no. 7, article e6377, 2009.

[251] S. O’Reilly, "miRNA in fibrosis: opportunities and challenges," Arthritis Research & Therapy, vol. 18, no. 1, p. 11, 2016.

[252] X.-M. Meng, D. J. Nikolic-Paterson, and H. Y. Lan, "TGF-β: the master regulator of fibrosis," Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, 2016.

[253] W. Qin, A. C. K. Chung, X. R. Huang et al., "TGF-β/Smad 3 signaling promotes renal fibrosis by inhibiting miR-29," Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1462–1474, 2011.

[254] P. Davoodian, R. Mehrdad, Y. H. Seyed et al., "The effect of TGF-B/smad signaling pathway blocking on the expression profiles of mi R-335, mi R-150, mi R-194, mi R-27a, mi R-199a of hepatic stellate cells (HSCs)," Gastroenterology and Hepatology from bed to bench, 2017.

[255] J. L. Gooch, C. King, C. E. Francis, P. S. Garcia, and Y. Bai, "Cyclosporine A alters expression of renal microRNAs: new insights into calcineurin inhibitor nephrotoxicity," PloS One, vol. 12, no. 4, article e0175242, 2017.

[256] K. Xiao, X. Luo, X. Wang, and Z. Gao, "MicroRNA-185 regulates transforming growth factor-β1 and collagen-1 in hypertrophic scar fibroblasts," Molecular Medicine Reports, vol. 15, no. 4, pp. 1489–1496, 2017.

[257] X. Jiang, E. Tsitsiou, S. E. Herrick, and M. A. Lindsay, "MicroRNAs and the regulation of fibrosis," The FEBs Journal, vol. 277, no. 9, pp. 2015–2021, 2010.

[258] X. Z. Zou, T. Liu, Z. C. Gong, C. P. Hu, and Z. Zhang, "MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases," European Journal of Pharmacology, vol. 796, pp. 190–206, 2017.

[259] D. A. Armstrong, A. B. Nymon, C. S. Ringelberg et al., "Pulmonary microRNA profiling: implications in upper lobe predominant lung disease," Clinical Epigenetics, vol. 9, no. 1, p. 56, 2017.

[260] D. Pignataro, S. Francia, F. Zanetta et al., "A missense MT-NDS mutation in differentiated Parkinson disease cytoplasmic hybrid induces ROS-dependent DNA damage response amplified by DROSHA," Scientific Reports, vol. 7, no. 1, p. 9528, 2017.

[261] S. Francia, F. Michelini, A. Saxena et al., "Site-specific DICER and DROSHA RNA products control the
DNA-damage response,” *Nature*, vol. 488, no. 7410, pp. 231–235, 2012.

[262] R. García, J. F. Nistal, D. Merino et al., “p-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling,” *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, vol. 1852, no. 7, pp. 1520–1530, 2015.

[263] B. N. Davis, A. C. Hilyard, G. Lagna, and A. Hata, “SMAD proteins control DROSHA-mediated microRNA maturation,” *Nature*, vol. 454, no. 7200, pp. 56–61, 2008.

[264] O.-S. Kwon, K. T. Kim, E. Lee et al., “Induction of MiR-21 by stereotactic body radiotherapy contributes to the pulmonary fibrotic response,” *PLoS One*, vol. 11, no. 5, article e0154942, 2016.

[265] R.-H. Liu, B. Ning, X.-E. Ma, W.-M. Gong, and T.-H. Jia, “Regulatory roles of microRNA-21 in fibrosis through interaction with diverse pathways (review),” *Molecular Medicine Reports*, vol. 13, no. 3, pp. 2359–2366, 2016.

[266] F. Gao, P. Liu, J. Narayanan et al., “Changes in miRNA in the lung and whole blood after whole thorax irradiation in rats,” *Scientific Reports*, vol. 7, no. 1, article 44132, 2017.

[267] S. Xu, N. Ding, H. Pei et al., “MiR-21 is involved in radiation-induced bystander effect,” *RNA Biology*, vol. 11, no. 9, pp. 1161–1170, 2014.

[268] Z. Ungvari, Z. Tucsek, D. Sosnowska et al., “Aging-induced dysregulation of Dicer1-dependent microRNA expression impairs angiogenic capacity of rat cerebral microvascular endothelial cells,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 68, no. 8, pp. 877–891, 2013.

[269] J. L. Wiesen and T. B. Tomasi, “Dicer is regulated by cellular stresses and interferons,” *Molecular Immunology*, vol. 46, no. 6, pp. 1222–1228, 2009.

[270] W. Lan, S. Chen, and L. Tong, “MicroRNA-215 regulates fibroblast function: insights from a human fibrotic disease,” *Cell Cycle*, vol. 14, no. 12, pp. 1973–1984, 2015.

[271] F. Yu, Z. Lin, J. Zheng, S. Gao, Z. Lu, and P. Dong, “Suppression of collagen synthesis by Dicer gene silencing in hepatic stellate cells,” *Molecular Medicine Reports*, vol. 9, no. 2, pp. 707–714, 2014.

[272] S. Shilo, S. Roy, S. Khanna, and C. K. Sen, “Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 3, pp. 471–477, 2008.

[273] H. Yano, R. Hamanaka, M. Nakamura-Ota, J. J. Zhang, N. Matsuo, and H. Yoshioka, “Regulation of type I collagen expression by microRNA-29 following ionizing radiation,” *Radiation and Environmental Biophysics*, vol. 57, no. 1, pp. 41–54, 2018.

[274] N. Duru, Y. Zhang, R. Gernapudi et al., “Loss of miR-140 is a key risk factor for radiation-induced lung fibrosis through reprogramming fibroblasts and macrophages,” *Scientific Reports*, vol. 6, no. 1, article 39572, 2016.

[275] B. A. Simone, D. Ly, J. E. Savage et al., “MicroRNA alterations driving acute and late stages of radiation-induced fibrosis in a murine skin model,” *International Journal of Radiation Oncology Biology Physics*, vol. 90, no. 1, pp. 44–52, 2014.

[276] S. Hamama, M. Z. Noman, P. Gervaz, S. Delanian, and M. C. Vozenen, “MiR-210: a potential therapeutic target against radiation–induced enteropathy,” *Radiotherapy and Oncology*, vol. 111, no. 2, pp. 219–221, 2014.

[277] M. Christofidou-Solomidou, R. Pietrofesa, E. Arguiri, M. A. McAlexander, and K. W. Witwer, “Dietary flaxseed modulates the miRNA profile in irradiated and non-irradiated murine lungs,” *Cancer Biology & Therapy*, vol. 15, no. 7, pp. 930–937, 2014.

[278] T.-K. T. Dinh, W. Fendler, J. Chalubińska-Fendler et al., “Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer,” *Radiation Oncology*, vol. 11, no. 1, p. 61, 2016.

[279] D. Zhao, Y. Luo, Y. Xia, J. J. Zhang, and Q. Xia, “MicroRNA-19b expression in human biliary atresia specimens and its role in BA-related fibrosis,” *Digestive Diseases and Sciences*, vol. 62, no. 3, pp. 689–698, 2017.

[280] Y. Jiao, C. Liu, F.-M. Cui et al., “Long intergenic non-coding RNA induced by X-ray irradiation regulates DNA damage response signaling in the human bronchial epithelial BEAS-2B cell line,” *Oncology Letters*, vol. 9, no. 1, pp. 169–176, 2015.

[281] Y. Chen, B. Yuan, Z. Wu, Y. Dong, L. Zhang, and Z. Zeng, “Microarray profiling of circular RNAs and the potential regulatory role of hsa_circ_0071410 in the activated human hepatic stellate cell induced by irradiation,” *Gene*, vol. 629, pp. 35–42, 2017.

[282] V. B. O’Leary, J. Smida, M. Matjanovskı et al., “The circRNA interactome-innovative hallmarks of the intra- and extracellular radiation response,” *Oncotarget*, vol. 8, no. 40, pp. 78397–78409, 2017.

[283] L. Shen, Q. Wang, R. Liu et al., “LncRNA Inc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA,” *Nucleic Acids Research*, vol. 46, no. 2, pp. 717–729, 2017.

[284] S. Xavier, E. Piek, M. Fujii et al., “Amelioration of radiation-induced fibrosis,” *Journal of Biological Chemistry*, vol. 279, no. 15, pp. 15167–15176, 2004.

[285] H. B. Forrester, D. M. de Kretser, T. Leong, J. Hagekryiauk, and C. N. Sprung, “Follistatin attenuates radiation-induced fibrosis in a murine model,” *PLoS One*, vol. 12, no. 3, article e0173788, 2017.

[286] S. Shrishrimal, E. Kosmaczek, A. Chatterjee, M. D. Tyson, and R. Oberley-Deegan, “The SOD mimic, MnTE-2-PyP, protects from chronic fibrosis and inflammation in irradiated normal pelvic tissues,” *Antioxidants*, vol. 6, no. 4, p. 87, 2017.

[287] E. A. Kosmaczek, A. Chatterjee, Q. Tong, C. Lin, and R. E. Oberley-Deegan, “MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells,” *Oncotarget*, vol. 7, no. 23, pp. 34532–34545, 2016.

[288] D. Leu, I. Spasojevic, H. Nguyen et al., “CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5+,” *Redox Biology*, vol. 12, pp. 864–871, 2017.

[289] Z. Rajic, A. Tovmasyan, O. L. de Santana et al., “Challenges encountered during development of Mn porphyrin-based, potent redox-active drug and superoxide dismutase mimic, MnTnBuOE-2-PyP5+, and its alkoxyalkyl analogues,” *Journal of Inorganic Biochemistry*, vol. 169, pp. 50–60, 2017.
S. C. Gad, D. W. Sullivan Jr, I. Spasojevic, C. V. Mujer, C. B. Spainhour, and J. D. Crapo, “Nonclinical safety and toxicokinetics of MnTnBuOE-2-PyP5+ (BMX-001),” *International Journal of Toxicology*, vol. 35, no. 4, pp. 438–453, 2016.

Z. N. Rabbani, I. Batinic-Haberle, M. S. Anscher et al., “Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury,” *International Journal of Radiation Oncology Biology Physics*, vol. 67, no. 2, pp. 573–580, 2007.

L. Packer, E. H. Witt, and H. J. Trittshler, “Alpha-lipoic acid as a biological antioxidant,” *Free Radical Biology and Medicine*, vol. 19, no. 2, pp. 227–250, 1995.

B. K. Jeong, J. H. Song, H. Jeong et al., “Protective effects of alpha-lipoic acid on radiation-induced small intestine injury in mice,” *Oncotarget*, vol. 7, no. 12, pp. 15105–15117, 2016.

J. H. Kim, K. M. Kim, M. H. Jung et al., “Protective effects of alpha-lipoic acid on radiation-induced salivary gland injury in rats,” *Oncotarget*, vol. 7, no. 20, 2016.

D. Karacetin, B. Yuvel, B. Leblebicioglu, O. Aksakal, O. Maral, and O. Incekara, “A randomized trial of amifostine as radio-protector in the radiotherapy of head and neck cancer,” *Journal of BU ON.: Official Journal of the Balkan Union of Oncology*, vol. 9, no. 1, pp. 23–26, 2004.

J. Gu, S. Zhu, X. Li, H. Wu, Y. Li, and F. Hua, “Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials,” *PloS One*, vol. 9, no. 5, article e95968, 2014.

J. C. Lee, P. A. Kinniry, E. Arguiri et al., “Phase Ib/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma,” *International Journal of Radiation Oncology Biology Physics*, vol. 90, no. 2, pp. 427–435, 2018.

S. Okumus, S. Taysi, M. Orkmez et al., “The effects of oral Ginkgo biloba supplementation on radiation-induced oxidative injury in the lens of rat,” *Pharmacognosy Magazine*, vol. 7, no. 26, pp. 141–145, 2011.

H. F. Zaki, G. M. Shaefy, N. E. Amin, A. S. Attia, and M. A. El-Ghazaly, “Neuroprotective effects of ginkgo biloba extract on brain damage induced by γ-radiation and lead acetate,” *International Journal of Scientific and Research Publications*, vol. 5, no. 9, pp. 2250–3153, 2015.

Z. Mei, X. Tian, J. Chen et al., “α7-nAchR agonist GTS-21 reduces radiation-induced lung injury,” *Oncology Reports*, vol. 40, no. 4, pp. 2287–2297, 2018.

A. Rezaeyan, G. H. Haddadi, M. Hosseinzadeh, M. Moradi, and M. Najafi, “Radioprotective effects of hesperidin on oxidative damages and histopathological changes induced by X-irradiation in rats heart tissue,” *Journal of Medical Physics*, vol. 41, no. 3, pp. 182–191, 2016.

R. M. Brand, M. W. Epperly, J. M. Stottlemeyer et al., “Topical mitochondria-targeted redox-cycling nitrooxide mitigates oxidative stress-induced skin damage,” *Journal of Investigative Dermatology*, vol. 137, no. 3, pp. 576–586, 2017.

M. Christofidou-Solomidou, R. A. Pietrofesa, E. Arguiri, C. Koumenis, and R. Segal, “Radiation mitigating properties of intranasally administered KL4surfactant in a murine
model of radiation-induced lung damage,” *Radiation Research*, vol. 188, no. 5, pp. 571–584, 2017.

[319] J. Li, J. Xu, Y. Lu et al., “MASM, a matrine derivative, offers radioprotection by modulating lethal total-body irradiation-induced multiple signaling pathways in Wistar rats,” *Molecules*, vol. 21, no. 5, p. 649, 2016.

[320] R. Tahamtan, A. Shabestani Monfared, Y. Tahamtani et al., “Radioprotective effect of melatonin on radiation-induced lung injury and lipid peroxidation in rats,” *Cell Journal*, vol. 17, no. 1, pp. 111–120, 2015.

[321] B. Gauter-Fleckenstein, J. S. Reboucas, K. Fleckenstein et al., “Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP5+,” *Redox Biology*, vol. 2, pp. 400–410, 2014.

[322] J. Cline, G. Dugan, J. Bourland et al., “Post-irradiation treatment with a superoxide dismutase mimic, MnTnHex-2-PyP5+, mitigates radiation injury in the lungs of non-human primates after whole-thorax exposure to ionizing radiation,” *Antioxidants*, vol. 7, no. 3, p. 40, 2018.

[323] A. Y. Makinde, X. Luo-Owen, A. Rizvi et al., “Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation,” *Anticancer Research*, vol. 29, no. 1, pp. 107–118, 2009.

[324] J. O. Archambeau, A. Tovmasyan, J. D. Crapo, and I. Batinc-Haberle, “Superoxide dismutase mimic, MnTnTE-2-PyP5+ ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum,” *Redox Biology*, vol. 1, no. 1, pp. 599–607, 2013.

[325] Z. Vujakovic, I. Batinc-Haberle, Z. N. Rabbani et al., “A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury,” *Free Radical Biology and Medicine*, vol. 33, no. 6, pp. 857–863, 2002.

[326] B. Gauter-Fleckenstein, K. Fleckenstein, K. Owzar et al., “Early and late administration of MnTnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage,” *Free Radical Biology and Medicine*, vol. 48, no. 8, pp. 1034–1043, 2010.

[327] D. H. Weitzel, A. Tovmasyan, K. A. Ashcraft et al., “Radioprotection of the brain white matter by Mn (III) N-butoxethylpyridylporphyrin–based superoxide dismutase mimic MnTnBuOE-2-PyP5+,” *Molecular Cancer Therapeutics*, vol. 14, no. 1, pp. 70–79, 2015.

[328] K. A. Ashcraft, M. K. Boss, A. Tovmasyan et al., “Novel manganese-porphyrin superoxide dismutase-mimetic widens the therapeutic margin in a preclinical head and neck cancer model,” *International Journal of Radiation Oncology Biology Physics*, vol. 93, no. 4, pp. 892–900, 2015.

[329] R. Neal, R. H. Matthews, P. Lutz, and N. Erkal, “Antioxidant role of N-acetyl cysteine isomers following high dose irradiation,” *Free Radical Biology and Medicine*, vol. 34, no. 6, pp. 689–695, 2003.

[330] C. Demirel, S. Kılıçkız, O. I. Ay, S. Gürgül, and N. Erdal, “Effect of N-acetylcysteine on radiation-induced genotoxicity and cytotoxicity in rat bone marrow,” *Journal of Radiation Research*, vol. 50, no. 1, pp. 43–50, 2009.

[331] O. Tascilar, G. Cakmak, A. Emre et al., “N-acetylcysteine attenuates the deleterious effects of radiation therapy on incisional wound healing in rats,” *Hippokratia*, vol. 18, no. 1, pp. 17–23, 2014.

[332] E. J. Chung, G. McKay-Corkum, S. Chung et al., “Truncated plasminogen activator inhibitor-1 protein protects from pulmonary fibrosis mediated by irradiation in a murine model,” *International Journal of Radiation Oncology Biology Physics*, vol. 94, no. 5, pp. 1163–1172, 2016.

[333] W. Qiu, B. Liu, M. Yi et al., “Antibiotic agent Pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model,” *Radiation Research*, vol. 190, no. 4, pp. 396–403, 2018.

[334] Y.-W. Sun, Y. Y. Zhang, X. J. Ke, X. J. Wu, Z. F. Chen, and P. Chi, “Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the Tgf-β1/smad/tgfβ signaling pathway,” *European Journal of Pharmacology*, vol. 822, pp. 199–206, 2018.

[335] N. L. Simone, B. P. Soule, L. Gerber et al., “Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study,” *Radiation Oncology*, vol. 2, no. 1, p. 19, 2007.

[336] S. Verma, B. Kalita, S. Bajaj, H. Prakash, A. K. Singh, and M. L. Gupta, “A combination of Podophyllotoxin and rutin alleviates radiation-induced pneumonitis and fibrosis through modulation of lung inflammation in mice,” *Frontiers in Immunology*, vol. 8, p. 658, 2017.

[337] J. S. Kim, N. K. Han, S. H. Kim, and H. J. Lee, “Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal transition,” *Oncotarget*, vol. 8, no. 41, pp. 69386–69397, 2017.

[338] I. A. Horton, F. Li, E. J. Chung et al., “Quercetin inhibits radiation-induced skin fibrosis,” *Radiation Research*, vol. 180, no. 2, pp. 205–215, 2013.

[339] H. Zhang, H. Yan, X. Zhou et al., “The protective effects of Resveratrol against radiation-induced intestinal injury,” *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 410, 2017.

[340] R. E. Carsten, A. M. Bachand, S. M. Bailey, and R. L. Ullrich, “Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells,” *Radiation Research*, vol. 169, no. 6, pp. 633–638, 2008.

[341] L. Xu, X. Yang, J. Cai et al., “Resveratrol attenuates radiation-induced salivary gland dysfunction in mice,” *The Laryngoscope*, vol. 123, no. 11, pp. E23–E29, 2013.

[342] Y. Simsek, S. Gurocak, Y. Turkoz et al., “Ameliorative effects of resveratrol on acute ovarian toxicity induced by total body irradiation in young adult rats,” *Journal of Pediatric and Adolescent Gynecology*, vol. 25, no. 4, pp. 262–266, 2012.

[343] H. Zhang, Z. Zhai, Y. Wang et al., “Resveratrol ameliorates ionizing radiation-induced long-term hematopoietic stem cell injury in mice,” *Free Radical Biology and Medicine*, vol. 54, pp. 40–50, 2013.

[344] Y. Son, H. J. Lee, J. K. Rho et al., “The ameliorative effect of sildibin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer,” *BMC Pulmonary Medicine*, vol. 15, no. 1, pp. 68, 2015.

[345] A. Gu, Y. Jie, L. Sun, S. Zhao, M. E, and Q. You, “RhnRgB-β protects the myocardium against irradiation-induced damage via the ErbB2-ERK-SIRT1 signaling pathway,” *PloS One*, vol. 10, no. 9, article e0137337, 2015.

[346] G. Jacobson, S. Bhatia, B. J. Smith, A. M. Button, K. Bodeker, and J. Buatti, “Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter,”
S. Yücel, B. Şahin, Z. Güral et al., “Impact of superoxide dismutase-gliadin on radiation-induced fibrosis: an experimental study,” *In Vivo*, vol. 30, no. 4, pp. 451–456, 2016.

I. U. Ahmad, J. D. Forman, F. H. Sarkar et al., “Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer,” *Nutrition and Cancer*, vol. 62, no. 7, pp. 996–1000, 2010.

G. G. Hillman, V. Singh-Gupta, F. H. Sarkar et al., “Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer,” *Nutrition and Cancer*, vol. 62, no. 7, pp. 996–1000, 2010.

G. G. Hillman, V. Singh-Gupta, F. H. Sarkar et al., “Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer,” *Nutrition and Cancer*, vol. 62, no. 7, pp. 996–1000, 2010.

W. B. Robb, C. Condron, M. Moriarty, T. N. Walsh, and D. J. Boucher-Hayes, “Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice,” *Irish Journal of Medical Science*, vol. 179, no. 1, pp. 99–105, 2010.

E. F. El-Maraghi, K. I. Abdel-Fattah, S. M. Soliman, and W. M. El-Sayed, “Taurine provides a time-dependent amelioration of the brain damage induced by γ-irradiation in rats,” *Journal of Hazardous Materials*, vol. 359, pp. 40–46, 2018.

W. Yang, J. Huang, B. Xiao et al., “Taurine protects mouse spermatocytes from ionizing radiation-induced damage through activation of Nrf 2/HO-1 signaling,” *Cellular Physiology and Biochemistry*, vol. 44, no. 4, pp. 1629–1639, 2017.

R. A. Rostock, J. A. Stryker, and A. B. Abt, “Evaluation of high-dose vitamin E as a radioprotective agent,” *Radiology*, vol. 136, no. 3, pp. 763–766, 1980.

N. S. Bese, F. Munzuroglu, B. Uslu et al., “Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats,” *Clinical Oncology*, vol. 19, no. 4, pp. 260–264, 2007.

V. K. Singh, O. O. Fatamni, S. Y. Wise, V. L. Newman, P. L. P. Romaine, and T. M. Seed, “The potentiation of the radioprotective efficacy of two medical countermeasures, gamma-tocotrienol and amifostine, by a combination prophylactic modality,” *Radiation Protection Dosimetry*, vol. 172, no. 1-3, pp. 302–310, 2016.

J.-H. Park, S. H. Ryu, E. K. Choi et al., “SKI 2162, an inhibitor of the TGF-β type I receptor (ALK5), inhibits radiation-induced fibrosis in mice,” *Oncotarget*, vol. 6, no. 6, pp. 4171–4179, 2015.

W. Chen, K. H. Shin, S. Kim et al., “hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF-β signaling,” *International Journal of Molecular Medicine*, vol. 41, no. 6, pp. 3211–3220, 2018.

Y. Dong, Y. Cheng, Q. Hou, J. Wu, D. Li, and H. Tian, “The protective effect of new compound XH-103 on radiation-induced GI syndrome,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 3920147, 9 pages, 2018.